The annual report for 2003 is presented to the Management Board by the Executive Director in accordance with Article 55(3) of Council Regulation (EEC) No 2309/93. It is forwarded to the European Parliament, Council, Commission and Member States. It is available in all official EU languages.

Previous annual reports and other reference documents are available from the EMEA web site www.emea.eu.int

This report covers activities of the EMEA in 2003. Chapter 1 sets out the activities of the EMEA within the European system. It includes the work of the Agency's Management Board, its partnership with national competent authorities and European institutions, and other general aspects of the EMEA, including transparency and the Agency's international activities.

The operational and technical work of the EMEA is reported in Chapter 2 on medicines for human use, Chapter 3 on veterinary medicines and Chapter 4 on inspection activities. Implementation of the EU telematics strategy, administration and other support activities are described in Chapters 5 and 6.

**Contents**

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Foreword by the Chairman of the Management Board</td>
<td>3</td>
</tr>
<tr>
<td>Introduction by the Executive Director</td>
<td>4</td>
</tr>
<tr>
<td>Structure of the EMEA</td>
<td>5</td>
</tr>
<tr>
<td><strong>Chapter 1 EMEA in the European System</strong></td>
<td>6</td>
</tr>
<tr>
<td>1.1 Management Board</td>
<td>6</td>
</tr>
<tr>
<td>1.2 Relations with competent authorities</td>
<td>6</td>
</tr>
<tr>
<td>1.3 EU enlargement</td>
<td>7</td>
</tr>
<tr>
<td>1.4 Transparency</td>
<td>8</td>
</tr>
<tr>
<td>1.5 Preparation for the review of the European system</td>
<td>8</td>
</tr>
<tr>
<td>1.6 Revision of EMEA fees</td>
<td>8</td>
</tr>
<tr>
<td>1.7 International partners</td>
<td>9</td>
</tr>
<tr>
<td>1.8 Corporate governance; integrated quality management and financial control</td>
<td>9</td>
</tr>
<tr>
<td><strong>Chapter 2 Medicines for Human Use</strong></td>
<td>10</td>
</tr>
<tr>
<td>2.1 Orphan medicinal products</td>
<td>11</td>
</tr>
<tr>
<td>2.2 Scientific advice and protocol assistance</td>
<td>13</td>
</tr>
<tr>
<td>2.3 Initial evaluation</td>
<td>15</td>
</tr>
<tr>
<td>2.4 Post-authorisation activities</td>
<td>17</td>
</tr>
<tr>
<td>2.5 Pharmacovigilance and maintenance activities</td>
<td>18</td>
</tr>
<tr>
<td>2.6 EudraVigilance</td>
<td>19</td>
</tr>
<tr>
<td>2.7 EMEA Risk Management Strategy</td>
<td>19</td>
</tr>
<tr>
<td>2.8 Arbitration and Community referrals</td>
<td>20</td>
</tr>
<tr>
<td>2.9 Regulatory guidance</td>
<td>20</td>
</tr>
<tr>
<td>2.10 Parallel distribution</td>
<td>21</td>
</tr>
<tr>
<td>2.11 Working parties and ad hoc groups</td>
<td>22</td>
</tr>
<tr>
<td>2.12 Enlargement and international activities</td>
<td>24</td>
</tr>
<tr>
<td>2.13 Mutual recognition facilitation group</td>
<td>24</td>
</tr>
<tr>
<td><strong>Chapter 3 Veterinary Medicines</strong></td>
<td>26</td>
</tr>
<tr>
<td>3.1 Scientific advice</td>
<td>27</td>
</tr>
<tr>
<td>3.2 Initial evaluation</td>
<td>27</td>
</tr>
<tr>
<td>3.3 Availability of medicines</td>
<td>28</td>
</tr>
<tr>
<td>3.4 Establishment of maximum residue limits for old substances</td>
<td>29</td>
</tr>
<tr>
<td>3.5 Post-authorisation activities</td>
<td>29</td>
</tr>
<tr>
<td>3.6 Pharmacovigilance and maintenance activities</td>
<td>30</td>
</tr>
<tr>
<td>3.7 Arbitration and Community referrals</td>
<td>30</td>
</tr>
<tr>
<td>3.8 Regulatory guidance</td>
<td>31</td>
</tr>
<tr>
<td>3.9 Enlargement and international activities</td>
<td>31</td>
</tr>
<tr>
<td>3.10 Veterinary mutual recognition facilitation group</td>
<td>32</td>
</tr>
<tr>
<td><strong>Chapter 4 Inspections</strong></td>
<td>33</td>
</tr>
<tr>
<td>4.1 Inspections</td>
<td>34</td>
</tr>
<tr>
<td>4.2 Mutual recognition agreements</td>
<td>35</td>
</tr>
<tr>
<td>4.3 Certificates of a medicinal product</td>
<td>36</td>
</tr>
<tr>
<td>4.4 Implementation of the clinical trials directive</td>
<td>36</td>
</tr>
<tr>
<td>4.5 Sampling and testing</td>
<td>36</td>
</tr>
<tr>
<td><strong>Chapter 5 EU telematics strategy</strong></td>
<td>37</td>
</tr>
<tr>
<td><strong>Chapter 6 Support activities</strong></td>
<td>39</td>
</tr>
<tr>
<td>6.1 Administration</td>
<td>39</td>
</tr>
<tr>
<td>6.2 IT and project management at the EMEA</td>
<td>41</td>
</tr>
<tr>
<td>6.3 Meeting management and conferences</td>
<td>43</td>
</tr>
<tr>
<td>6.4 Document management and publishing</td>
<td>44</td>
</tr>
<tr>
<td><strong>Annexes</strong></td>
<td>45</td>
</tr>
<tr>
<td>Annex 1 Members of the Management Board</td>
<td>47</td>
</tr>
<tr>
<td>Annex 2 Members of the Committee for Proprietary Medicinal Products</td>
<td>48</td>
</tr>
<tr>
<td>Annex 3 Members of the Committee for Veterinary Medicinal Products</td>
<td>50</td>
</tr>
<tr>
<td>Annex 4 Members of the Committee for Orphan Medicinal Products</td>
<td>52</td>
</tr>
<tr>
<td>Annex 5 National competent authority partners</td>
<td>53</td>
</tr>
<tr>
<td>Annex 6 EMEA budget summaries 2002 – 2004</td>
<td>57</td>
</tr>
<tr>
<td>Annex 7 CPMP opinions in 2003 on medicinal products for human use</td>
<td>58</td>
</tr>
<tr>
<td>Annex 8 CVMP opinions in 2003 on medicinal products for veterinary use</td>
<td>61</td>
</tr>
<tr>
<td>Annex 9 COMP opinions in 2003 on designation of orphan medicinal products</td>
<td>63</td>
</tr>
<tr>
<td>Annex 10 Guidelines and working documents in 2003</td>
<td>66</td>
</tr>
<tr>
<td>Annex 11 Arbitration and Community referrals overview 2003</td>
<td>78</td>
</tr>
<tr>
<td>Annex 12 EMEA contact points</td>
<td>79</td>
</tr>
</tbody>
</table>
The European system offers two routes for authorisation of medicinal products. The EMEA plays a role in both procedures:

- The centralised procedure is compulsory for medicinal products derived from biotechnology and available at the request of companies for other innovative new products. Applications are submitted directly to the EMEA. At the conclusion of the scientific evaluation, undertaken in 210 days within the Agency, the opinion of the scientific committee is transmitted to the European Commission to be transformed into a single market authorisation applying to the whole European Union.

- The decentralised procedure (or mutual recognition procedure) applies to the majority of conventional medicinal products and is based upon the principle of mutual recognition of national authorisations. It provides for the extension of marketing authorisations granted by one Member State to one or more other Member States identified by the applicant. Where the original national authorisation cannot be recognised, the points in dispute are submitted to the EMEA for arbitration. The opinion of the scientific committee is transmitted to the European Commission.

The European Commission adopts its decision with the assistance of a standing committee composed of representatives of the Member States.
Foreword by the Chairman of the Management Board
Philippe Duneton

This ninth annual report gives a detailed and precise account of the work and efforts devoted by the Agency to achieve the goals of the 2003 work programme.

The primary objective achieved by the Agency was to guarantee a high level evaluation and control of the safety, quality and efficacy of medicines for human and veterinary use in Europe. It also took up other challenges and in particular prepared for the enlargement of the European Union with the ten new Member States, contributed in an active way to the review of pharmaceutical regulation, continued to further improve its operation and that of its scientific committees, and developed the corresponding information systems. The Agency also reinforced the close links established with the national competent authorities, an essential condition in achieving our mission of public health.

This report shows the great diversity of the work undertaken by the EMEA within its three scientific committees, working groups and ad hoc groups, in fields as varied as paediatric drugs, gene therapy, pharmacogenomics, pandemic influenza vaccine, and herbal medicinal products. This reflects the actions engaged by the Agency to support the delivery of scientific opinions and consideration of pharmacovigilance aspects in the early stages of the development of new pharmaceutical products.

Actions taken in 2003 by the EMEA and heads of the national agencies in regard to pharmacovigilance are an example of our capacity to join forces in pursuing the same objective of public health. This work constitutes remarkable progress in the setting up of a European risk management strategy aimed at reinforcing the safety of all pharmaceutical products being put on the European market, whether or not through the centralised procedure. In the same way, the work carried out in the field of pharmacovigilance for veterinary medicinal products allowed implementation of several specific actions to consolidate progress already made.

The Management Board examined with satisfaction the report on the first three years of operation of the European policy on orphan drugs. It encouraged work on veterinary medicinal products and resistance to antibiotics, and it adopted proposals in favour of the development of scientific opinions on veterinary medicinal products for minor use and minor species.

The Board also supported the good corporate governance conducted in 2003 that aimed at reinforcing the quality and safety of work carried out by the Agency, particularly the first external audit of the Committee for Proprietary Medicinal Products, creation of a new internal audit structure and new measures in support of the Agency’s policy on transparency.

The EMEA took an active part in the final phase of the PERF III programme, and invited the national authorities of accession countries to participate in the work of the scientific committees, working groups and Management Board as observers in order to familiarise themselves with European procedures. These preparatory actions for the enlargement of the Community have ensured that our system remains as effective and reactive as possible.

I wish to underline once again the quality of the commitment and competence of the EMEA staff, under the authority of the Executive Director, as well as that of the members and experts of the scientific committees, and the network of competent authorities. Finally, I wish to thank the colleagues of the Management Board for their advice and their judicious and constructive remarks that enable us to contribute efficiently to the development of the EMEA and of our system for evaluating the safety, quality and efficacy of pharmaceuticals in Europe.
In terms of the public health outcome, the Agency’s scientific committees dealt with a number of important new medicines, particularly in the field of HIV/AIDS, cancer, diabetes, Alzheimer’s disease, rare and severe cardiovascular, pulmonary and congenital conditions. The CPMP adopted 24 positive opinions, of which 7 were for orphan medicines for rare diseases and conditions, with an average review and processing time of some 8 months.

Activities in the veterinary field were marked in particular by a strong number of applications for new medicines. We also made good progress in our initiatives on pharmacovigilance for veterinary medicines and on improving availability of medicines for minor uses and minor species.

This was also the first year when the EMEA had responsibility for implementation of the EU telematics strategy for pharmaceuticals. We have worked closely with the Member States and the European Commission to achieve the milestones in the strategy. We were able to deliver the first prototype of the European database of medicines (EuroPharm), launch the initial version of the European viewing tool for electronic submissions. The telematics strategy continued to expand in scope and number of projects with the addition of a new database for reporting suspected unexpected serious adverse reactions (SUSARs) and the clinical trials database (EudraCT) in 2003.

Recognising the increasing international context within which both the pharmaceutical industry and regulators operate, the European Commission and EMEA concluded a confidentiality arrangement with the US Food and Drug Administration in 2003. This arrangement will not only help the two agencies work better together, but it will also help industry, particularly in allowing us to give parallel scientific advice to companies as they develop new medicines.

These issues were in the background to what will certainly be one of the more important events in the recent history of the European Union – enlargement in May 2004. The 5-year Pan-European Regulatory Forum (PERF) programme came to an end in 2003 and represents a considerable effort on the part of the EMEA and all national competent authorities to prepare ourselves and assist colleagues in the accession countries to ensure a smooth transition into the European family.
Structure of the EMEA

Management Board

Executive Director

Integrated quality management / audit

Executive support

Pre-Authorisation Evaluation of Medicines for Human Use
- Scientific advice and orphan drugs
- Quality of medicines
- Safety and efficacy of medicines

Post-Authorisation Evaluation of Medicines for Human Use
- Regulatory affairs and organisational support
- Pharmacovigilance and post-authorisation safety and efficacy of medicine

Veterinary Medicines and Inspections
- Veterinary marketing authorisation procedures
- Safety of veterinary medicines
- Inspections

COMP
Committee for Orphan Medicinal Products

CPMP
Committee for Proprietary Medicinal Products

CVMP
Committee for Veterinary Medicinal Products

Administration
- Personnel and budget
- Infrastructure services
- Accounting

European Union institutions
- European Pharmacopoeia

National competent authorities
- 3 000 European experts

Communications and Networking
- Document management and publishing
- Meeting management and conferences
- Project management
- Information technology
Chapter 1
EMEA in the European system

1.1 Management Board

Chairman of the Management Board
Philippe DUNETON

Vice-chairman of the Management Board
Jytte LYNGVIG

The Management Board met four times in 2003.

20 February 2003
• Management Board began a new mandate
• Elected Keith Jones and Philippe Duneton as chairman and vice-chairman
• Adopted 2003 draft work programme and preliminary draft budget totalling € 84 224 000

5 June 2003
• Observers from EU accession countries began attending Management Board on a regular basis
• New EMEA financial regulation and implementing rules were provisionally adopted
• Decision taken to create an Audit Advisory Committee

2 October 2003
• Board adopted 23 recommendations aimed at improving EMEA transparency
• Pilot project approved for free scientific advice for new veterinary medicines for minor uses and minor species

18 December 2003
• Election of Philippe Duneton and Jytte Lyngvig as chairman and vice-chairman
• Adopted 2004 work programme and budget totalling € 96 619 000

The Board heard regular reports during the year on both preparations for enlargement and the implementation by the EMEA of the EU telematics strategy projects.

1.2 Relations with competent authorities

Useful web sites:

Heads of agencies for medicines for human medicines
http://heads.medagencies.org

Heads of European veterinary regulatory authorities for medicinal products
http://www.hevra.org/

Mutual recognition product index
http://mri.medagencies.org

The Agency participated in all meetings of the heads of national competent authorities for human and veterinary medicines in 2003. Topics included resource planning, the European telematics strategy, risk management strategies, pharmacovigilance and training. The Agency also worked closely with the European Commission and national authorities through the telematics management structure and implementation groups.

The heads of human and veterinary medicines agencies of the EU accession countries met at the Agency in September and October as part of the preparations for future membership. A delegation from the Romanian national inspection service visited the Agency in June 2003.

The EMEA was please to welcome the Italian Minister of Health, Prof. Girolamo Sirchia, as part of the preparations for the Italian EU presidency. There were also delegations from the Greek, Swedish and UK national authorities during the course of 2003. The Agency also received representatives from the German, French and British national parliaments.

The EMEA paid € 30 075 000 in 2003 to national competent authorities for scientific services provided for the evaluation of medicines for human and veterinary use. This represents 31 % of the EMEA budget.
1.3 EU enlargement

Useful web sites:

- Pan-European Regulatory Forum
  http://perf.eudra.org
- Collaboration Agreement of Drug Regulatory Authorities in European Union Associated Countries
  http://www.cadreac.org
- Collaboration Agreement between Veterinary Drug Registration Institutions
  http://www.cavdri.info

Web sites for national authorities of the accession countries:

- **Cyprus**
  Ministry of Health, Ministry of Agriculture
  http://www.pio.gov.cy

- **Czech Republic**
  State Institute for Drug Control
  http://www.sukl.cz
  Institute for the State Control of Veterinary Biologicals and Medicaments
  http://www.uskvbl.cz

- **Estonia**
  State Agency of Medicines
  http://www.sam.ee

- **Hungary**
  National Institute of Pharmacy, Institute for Veterinary Medicinal Products
  http://www.ogyi.hu

- **Latvia**
  Food and Veterinary Service
  http://zaale.vza.gov.lv

- **Lithuania**
  State Medicines Control Agency
  http://www.vvkt.lt
  State Food and Veterinary Service
  http://www.vet.lt

Following signature of the accession treaties, the national authorities of the accession candidate countries were invited to send observers to EMEA scientific committees and working parties with effect from April 2003.

The Agency continued to participate actively in the third and final phase of the Pan-European Regulatory Forum for Pharmaceuticals (PERF III), which was successfully concluded in December 2003. The forum is funded by the European Commission PHARE programme. Part of the efforts in this last part of the PERF activities were aimed at informing representatives of patient and health care professional associations about the implications of EU enlargement.

Other areas of activity included preparations for the availability of information on centrally authorised medicines in all the 9 new official EU languages. This was done in cooperation with the national authorities of the accession countries. The EMEA also worked towards ensuring that all the new authorities were linked to the EudraNet communications network. Efforts were also made to recruit interims, new staff members and national experts on secondment from the accession countries.

While Bulgaria and Romania are not part of the accession on 1 May 2004, they continued to participate in the work of the EMEA through their CADREAC and CAVDRI representatives.

**Malta**
Medicines Regulatory Unit
http://www.health.gov.mt/mru

**Poland**
Office for Medicinal Products
http://www.urpl.gov.pl

**Slovak Republic**
State Institute for Drug Control
Institute for State Control of Veterinary Biologicals and Medicaments
http://www.sukl.sk

**Slovenia**
Agency for Medicinal Products (Ministry of Health), Ministry of Agriculture, Forestry and Food
http://www2.gov.si/mz/mz-splet.nsf
1.4 Transparency

On a proposal from the Executive Director, the Management Board adopted a series of 23 recommendations in October 2003 following a public consultation exercise. The recommendations aim both at improving existing transparency and public access initiatives and introduce new proposals. The scope of the recommendations was intended to complement the measures under discussion by the European Parliament and Council as part of the review of pharmaceutical legislation.

The EMEA founding regulation was amended in June 2003 bringing the Agency within the scope of EU legislation on access to documents (Regulation (EC) No 1049/2001). This change came into force in October 2003. Preparations were made to adapt the existing rules on access to documents to the requirements of the Regulation with a view to their adoption by the Management Board at the beginning of 2004.

The three scientific committees continued their work in maximising relations with interested parties. The CPMP established a working group with patient representatives, which met in May, September and December 2003.

The EMEA web site underwent a number of changes during the year. More than 10,000 documents were either published or revised in 2003. A new part of the web site was launched relating to inspections to increase the visibility and access to procedural documents, guidance and inspection-related news. Work on a new web site progressed in 2003 and takes into account comments made by contributors to the transparency public consultation exercise, including the development of a new search tool.

1.5 Preparation for the review of the European system

The EMEA contributed actively to the review of pharmaceutical legislation. At the invitation of both the Greek and Italian presidencies, the Agency participated at all Council of Ministers working party meetings in 2003.


Work on preparation for the implementation of the revised legislation became more important as it was realised that at least part of the new Regulation would come into force in early 2004.

1.6 Revision of EMEA fees

The level of fees payable to the EMEA by applicants for and holders of Community marketing authorisations were revised by Commission Regulation (EC) No 494/2003 in March 2003.

As part of efforts to simplify administrative arrangements, the Management Board adopted a decision in June 2003 consolidating all implementing rules for the fee regulation. This was published on the EMEA web site. The consolidated decision was amended in October and December 2003.

An internal EMEA task force began work on the future financing of the Agency, in parallel to the review of EU pharmaceutical legislation. The Agency has been working together with the Management Board/European Commission in preparing for new fee structure to take into account the implications of the legislation.
1.7 International partners

Useful web sites:
- International Conference on Harmonisation
  http://www.ich.org
- Veterinary International Conference on Harmonisation
  http://vich.eudra.org
- World Health Organisation
  http://www.who.int

The Agency continued its commitment to and active participation in the two international conferences on harmonisation for human and veterinary medicines. Both the ICH and VICH processes made good progress in 2003 and this is described in Chapters 2 and 3.

The EMEA provided technical support to the European Commission delegation to the Codex Alimentarius, in particular to the 13th Codex Alimentarius Committee for Residues of Veterinary Drugs in Food in Washington, DC.

The EMEA continued its collaboration with WHO in particular on INNs, in preparation of the scientific opinion in the framework of the EU legislation and on pharmacovigilance aspects. WHO experts have participated to EMEA Scientific Committees meetings on various Public Health issues or for products under review.

EMEA has also participated on a regular basis to meetings organised by CIOMS.

The EMEA welcomed delegations from a number of non-EU countries in 2003, including from Australia, Canada, China, Japan, New Zealand, Taiwan, Vietnam and the US. The Agency was pleased to host a meeting of the VICH Steering Committee in May 2003.

The EMEA hosted the annual EU-US Food and Drug Administration bilateral for the first time. An exchange of letters on a confidentiality arrangement was concluded between the FDA, European Commission and EMEA on 12 September 2003. A detailed implementation plan is under discussion between the FDA and EMEA.

1.8 Corporate governance: integrated quality management and financial control

A programme of benchmarking visits to the national authorities in the accession countries, including Bulgaria and Romania, was launched in April 2003. The visits are intended to enhance the implementation of an integrated quality management system to ensure good regulatory practices in the EU. The visits also intended to provide targeted audit training for participating quality professionals in the EU and accession country agencies. The audit teams were composed of representatives from national authorities of existing and future Member States and from the European Directorate of the Quality of Medicines (EDQM).

The annual programme of internal audits continued, including a number of integrated management audits conducted together with the Agency’s financial controller. Work also progressed on the drafting of a risk register for the Agency. The results of the risk analysis were shared with the European Commission Internal Audit Service (IAS), which will use this information in preparation for the first IAS audit of the EMEA.

An audit of the CPMP was conducted in June 2003. This was the first audit outside of the secretariat and involved two auditors from national inspection services.

The Management Board endorsed a proposal from the Executive Director in June 2003 to establish an Audit Advisory Committee. The Committee will advise the Director on an annual audit programme and be composed of external and internal members.

As part of the introduction of new financial regulations for the European Commission and all EU bodies, the post of financial controller was abolished at the EMEA during 2003. A new system of ex ante and ex post controls and internal audits was introduced.
Chapter 2
Medicines for human use

Overview

Unit for the Pre-authorisation evaluation of medicines for human use
Head of Unit
Patrick LE COURTOIS
Head of Sector for scientific advice and orphan drugs
Agnès SAINT RAYMOND
Head of Sector for quality of medicines
John PURVES
Head of Sector for safety and efficacy of medicines
Isabelle MOULON
Deputy Head of Sector for safety and efficacy of medicines
Marisa PAPALUCA AMATI

Unit for the Post-authorisation evaluation of medicines for human use
Head of Unit
Noël WATHION
Head of Sector for regulatory affairs and organisational support
Tony HUMPHREYS
Head of Sector for pharmacovigilance and post-authorisation safety and efficacy of medicines
Panos TSINTIS
Deputy Head of Sector for pharmacovigilance and post-authorisation safety and efficacy of medicines
Sabine BROSCH

See Annex 2 and 4 for Committee members, working parties and ad hoc groups.

Priorities for medicines for human use in 2003 – progress report

• The total number of new applications for marketing authorisation received in 2003 has been higher than initially planned following the drop seen in 2002, particularly for non-orphan products. The EMEA adhered to timelines for all completed procedures. Summaries of opinion were published for all applications at the time of opinion and EPARs were made public in the 2 weeks period after the European Commission decision.

• There has been a steady progress in the further development of the EudraVigilance database and dataprocessing network following release of version 6.0 of the system. Development of the SUSAR module of EudraVigilance has started and will be implemented during 2004, hence leading to the electronic receipt of adverse reaction reports from clinical trials. Delays have, however, occurred as regards the implementation of the EudraVigilance project, due to a delay in the electronic reporting by national competent authorities and pharmaceutical industry.

• 2003 has seen a sharp increase in Type II Variations relating to clinical safety, efficacy and quality aspects. The new Variation Regulation entered into force in the autumn. Relevant post-authorisation guidance was developed and published on the Agency website. A new type of minor variations has to be directly managed by the Agency.

• Discussions continued at Heads of Agencies level, with the participation of the Agency, on the further development of a EU Risk Management Strategy. As part of the Agency’s strategy the CPMP agreed on a revised procedure for the handling of safety concerns for centrally processed applications, both pre- and post-authorisation. Such revised procedure, which contributes to the concept of life-cycle management of medicines, will be implemented in 2004.

• A new procedure for scientific advice and protocol assistance has been implemented early 2003 allowing for additional meeting days for the Scientific Advice Working Group outside of the CPMP week. The composition of the group has been modified, more expertise is involved and the rate of face-to-face meetings has increased. The mean duration of the procedure has been reduced while the number of applications increased substantially. A survey performed in 2003 shows a high level of satisfaction with the new procedures from users while the positive outcome, at the time of marketing authorisation phase, is now evidenced.
Applications for obtaining EU orphan status for products aiming at treating rare diseases remain stable and the duration of the procedure is constantly below the official timeframe. Post designation activities are rapidly increasing in relation with the number of products designated and getting a marketing authorisation but have been nevertheless managed within time frames.

2.1 Orphan medicinal products

Management and organisation of the COMP

The Committee for Orphan Medicinal Products (COMP) is responsible for making recommendations to the European Commission for the designation of orphan medicinal products intended for rare diseases. The COMP has also responsibilities for advising the European Commission on the development of an orphan drug policy and for providing assistance in liaison with international partners and patient organisations.


The level of applications for designation of orphan medicines remained high, with 15% more applications than forecast. There have now been more than 300 applications since the implementation of the orphan medicines Regulation (EC) No 141/2000. This indicates a continuing interest on the part of sponsors to benefit from the incentives of the Regulation.

Pre-submission meetings were held for 87% of applications. The quality of applications improved over time, particularly when there was a pre-submission meeting and this is shown in the decreased time to validation that was 33 days while the average time for an application for which a pre-submission meeting was not held was 67 days.

A total of 35 applications for designation were withdrawn in 2003 since the sponsors were not able to fully justify their requests.

The average time taken by the COMP to adopt recommendations on the designation of orphan medicines in 2003 was 67 days in average, below the target 90 days. The time taken to transform opinions on designation into European Commission decision has been improved and the overall process for designation remains to a large extend below the 120-day timeframe (average 44 days).

The second 3-year mandate of the COMP started in May 2003. Since July 2003, non-voting members from Norway, Iceland and Liechtenstein can participate in the COMP as their countries have now transposed into their national laws the orphan regulation.
Of the medicinal products that received an opinion from the COMP in 2003, 12 % are aimed at treating conditions that only affect children and 25 % are aimed at diseases that affect both adults and children.

The COMP created an ad-hoc group on significant benefit to provide clearer advice to sponsors on this criterion for designation and reviewed a number of guidance documents to facilitate the preparation of applications and annual reports by sponsors. Details of these documents are given in Annex 9.

The EMEA information brochure on orphan medicinal products was updated in 2003. A workshop with academia and health professionals was held in October 2003 to address the issues of rare diseases which prevalence is either increasing or decreasing over time.

Designated orphan medicinal products are entitled to receive reductions on fees levied by the EMEA when applications are made for protocol assistance, marketing authorisation or other regulatory actions. A special contribution voted each year by the Council and the European Parliament is allocated for these reductions. Fee reductions in 2003 were mainly used for applications for marketing authorisation and protocol assistance.

More than half of the medicinal products that received a COMP opinion in 2003 were developed for the treatment of cancers, diseases of immunological origin and metabolic diseases, of which a number are related to enzyme deficiencies. Details of designation opinions in 2003 are given in Annex 9.

In 2003 summaries of COMP opinions were regularly published on the EMEA web site and now include translation of the rare disease’s name and the product’s in all languages. These documents provide brief information in lay terms on the expected mode of action of the products and a description of the orphan condition. Summaries of COMP opinions are published in English, following the decision on orphan designation made by the European Commission.

The regular review of annual reports for designated orphan medicinal products provides an update on the development of designated orphan products up to the granting of a marketing authorisation. One hundred twenty seven annual reports were reviewed in 2003, a 27% increase of the planned activities.
Use of EU special contribution for Orphan medicines 2003

<table>
<thead>
<tr>
<th>Category</th>
<th>2001</th>
<th>2002</th>
<th>2003</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protocol assistance</td>
<td>56</td>
<td>59</td>
<td>72</td>
</tr>
<tr>
<td>Inspections</td>
<td>5</td>
<td>15</td>
<td>25</td>
</tr>
<tr>
<td>Marking authorisation</td>
<td>65</td>
<td>65</td>
<td>75</td>
</tr>
<tr>
<td>Post-authorisation</td>
<td>4</td>
<td>13</td>
<td>22</td>
</tr>
</tbody>
</table>

2.2 Scientific advice and protocol assistance

Beginning of January 2003, a new group and a new procedure for scientific advice or protocol assistances were set up. The Scientific Advice Working Group (SAWG) of the CPMP is responsible for providing advice to sponsors on quality, safety or efficacy related aspects of medicinal products. Designated orphan medicinal products are entitled to receive scientific advice in the form of protocol assistance on the same issues and on significant benefit as one of the criteria for orphan designation. The Group met 11 times in 2003.

The meetings of the SAWG take place in between CPMP meetings and last for 2 full days. The number of face-to-face meetings with sponsors and the group has increased considerably as the time available for such meetings was previously missing. The duration of the procedure has been shortened by nearly one week. In addition an exceptional 100-day procedure for complex issues and 40-day fast procedure for simple requests have been set up.

Overall the workload increased by more than 20 %.

Oral explanation meetings with sponsor companies were held in the majority of cases were advice was given in 2003 and for all protocol assistance procedures. Pre-submission meetings increased dramatically by about 100 % as compared to 2002.

The number of scientific advice activities in 2003 has increased both for the number of requests received and advice finalised, exceeding expectations by 10-15 %. Protocol assistance increased by nearly 50 %. This increase shows the high interest of companies developing medicines for rare diseases in receiving help along the development of their orphan product.
The impact of scientific advice on the outcome of the scientific evaluation at the stage of marketing authorisation was assessed. In 2003 up to 45% of applicants for marketing authorisation have received scientific advice. The chances of favourable outcome at the time of the opinion of the Committee for Proprietary Medicinal Products are increased for products having received scientific advice or protocol assistance.

The mean duration of the procedures was about 82 days, an improvement related to the new procedure. Including validation time the overall procedure took 100 days.

Of the requests for scientific advice and protocol assistance finalised in 2003, two-thirds related to the clinical aspects of the development of medicinal products. Early consultation of the group was observed with phase I trials representing 18% compared to 2% in 2002. 56% of requests related to phase III clinical trials.

The impact of scientific advice on the outcome of the scientific evaluation at the stage of marketing authorisation was assessed. In 2003 up to 45% of applicants for marketing authorisation have received scientific advice. The chances of favourable outcome at the time of the opinion of the Committee for Proprietary Medicinal Products are increased for products having received scientific advice or protocol assistance.

Of the requests for scientific advice and protocol assistance finalised in 2003, two-thirds related to the clinical aspects of the development of medicinal products. Early consultation of the group was observed with phase I trials representing 18% compared to 2% in 2002. 56% of requests related to phase III clinical trials.
2.3 Initial evaluation

Initial applications for marketing authorisation were above target for new drugs (non-orphan), with 32 applications received out of the 22 forecast for the entire year.

The number of marketing authorisation applications for designated orphan medicines was below target, with 7 applications received out of the total 16 forecast for 2003.

There were 24 positive opinions (including 7 orphan drugs), 2 negative opinions for orphan medicines, which after appeal got further negative opinions and 4 withdrawals (including 3 orphan drugs). This brings to 13 the number of orphan medicinal products available to patients in the EU.

A total of 69 applications were under review within the year. This indicates that the number of medicinal products reaching the stage of marketing applications reverted to the figures reached in 2000 and 2001 and increased slightly compared to the previous year when a significant drop was observed. A small number of products submitted in 2003 had been planned initially for submission in 2002 but were delayed. There were fewer multiple applications than in 2000 and 2001, and a lower proportion of products aimed at treating rare diseases.

A total of 11 marketing authorisations were issued for designated orphan medicinal products, out of which 4 were in 2003. 13 more applications for designated orphan medicinal products are ongoing.

A large number of the applications were submitted either fully or partially using the new international common technical document (CTD) format, which became a mandatory requirement in the EU from mid-2003. The first electronic CTD was submitted late 2003.

Three therapeutic areas (Oncology, anti-infectives and neurology) represented in 2003 70 % of the applications received.
Similarly, some flexibility has been introduced concerning clock stop during the procedure, allowing in particular cases, on the request of applicants, to extend the period for preparation of additional information or data. This increase in clock stop time has also to be compared to the lower rate of withdrawals during the same period of time.

Summaries of opinions were published, for all applications, at the time of the opinion given by the CPMP in all cases. European Public Assessment Reports (EPARs) were published within 2 weeks of the Commission decision in most cases. However, delays were experienced because of disagreement between the companies and EMEA and the CPMP rapporteurs on the content of the EPAR. Procedures in this respect have been reviewed.

Overall these medicinal products will benefit patients affected by diseases such as infections, AIDS cancer, diabetes, Alzheimer’s disease, rare and severe cardiovascular and pulmonary conditions or rare congenital deficiencies. Details of all CPMP opinions are given in Annex 7.

Committee for Proprietary Medicinal Products

The CPMP held twelve plenary meetings in 2003. An extraordinary meeting was held in April 2003 to examine safety concerns for centrally authorised hexavalent vaccines. This reflects the growing workload of the Committee in post-authorisation activities. The membership of the CPMP is provided in Annex 2.

As planned, the CPMP, through its Organisational Matters Group (ORGAM), kept its working practices under close review and introduced any necessary changes to improve the functioning and operation of the Committee and the centralised procedure. In addition, as part of the Agency’s ongoing integrated quality management initiatives, an audit of the CPMP was performed in June 2003. This led to a number of initiatives, resulting in an EMEA action plan to further improve its processes in relation to medicines for human use.

The Committee established three therapeutic advisory groups in 2003 in the fields of oncology, anti-infectives and diagnostics. Further to a first joint meeting of the three therapeutic advisory groups held in June 2003, further separate meetings were organised during the remainder of 2003.
2.4 Post-authorisation activities

The number of variations to marketing authorisations increased significantly in 2003. The number of minor (type I) variations was 12 % over target. Also major (type II) variations were running over target with a 67 % increase over planned figures. Such increase related to efficacy/clinical safety aspects as well as quality aspects. With respect to procedures finalised in 2003 the results were as an average 32% over projections for minor and major changes.

Following the entry into force of new Community legislation on variations in October 2003, the procedures for processing the new type IA and type IB variations were established and implemented. The impact of this change to the legislation will be assessed in 2004.
As planned, adherence to regulatory timelines for active review time by the CPMP was achieved. The evaluation times given in the above charts show that the majority of Type I variations are managed in less than 30 days while an extension of the time frame is necessary for the rest. In terms of processing Type II variations, 71% are processed in less than 120 days, whilst 29% required an extension of that time frame.

Although it was planned to increase the Agency’s transparency in the post-authorisation phase, further discussion on this issue before implementation was necessary. As a consequence, a consultation with the Agency’s stakeholders on its transparency policy took place in 2003. It resulted in the adoption by the Management Board in October 2003 of recommendations in different fields including the post-authorisation area.

### 2.5 Pharmacovigilance and maintenance activities

#### Useful website:

**EudraVigilance**  
http://eudravigilance.emea.eu.int

A total of 45 538 adverse drug reaction reports were received by the Agency during 2003 for centrally authorised medicinal products. This represents an overall 11% increase in the level of reporting over 2002, which was in line with the forecast. 15 017 reports were from EU sources and 30 521 from outside the EU. There has been a workload increase of 66% in specific obligations and follow-up measures handled by the EMEA and CPMP.

In terms of periodic safety updates, work throughput continued to increase in 2003 compared with 2002. These increased workloads mirror the increases in new medicinal products, authorised in 2003, being subject to follow-up activities and 6-monthly PSUR cycle. A total of 21 annual reassessments were handled by EMEA.

Three urgent safety restrictions were completed during 2003 introducing important new product information to support safe use of the medicines concerned. Appropriate communication to healthcare professionals and the public accompanied these activities.

1 This figure refers to all reports received either on paper or electronically by the Agency.
2.6 EudraVigilance

Further development of the EudraVigilance project proceeded as planned. However progress with the implementation of the EudraVigilance project was hampered in particular due to delayed implementation at the level of national competent authorities and pharmaceutical companies.

In 2003, the implementation of the electronic transmission of individual case safety reports (ICSRs) to EudraVigilance was achieved with an additional 2 Member State authorities and 13 pharmaceutical companies. In total, three national competent authorities and 18 pharmaceutical companies were in production at the end of 2003.

In total, ICSRs referring to 25,190 individual cases were reported electronically to EudraVigilance during 2003. This figure refers to reports for centrally authorised medicinal products as well as those authorised through the mutual recognition and national procedure.

In parallel a further 4 national competent authorities and 27 pharmaceutical companies entered into the testing phase. Five national competent authorities have opted or are in a process of evaluating to use a copy of the EudraVigilance system at national level. Three national competent authorities have installed and tested EudraVigilance version 6.0 locally in 2003.

Version 6.0 of the EudraVigilance system was launched in spring 2003. In addition, a special web-based tool was designed to support the electronic reporting by small and medium sized enterprises and is due to be released early in 2004 following appropriate training. A full training programme for EudraVigilance users was elaborated.

Some 23 meetings were held with national competent authorities and pharmaceutical industry in order to further support the implementation phase of EudraVigilance. Added functionality is planned for data analysis by the application of a ‘data warehouse’ concept allowing for the implementation of standard signal detection and data mining methodologies.

Preparations for future interaction with healthcare professionals and patient groups were begun as part of the Agency’s transparency initiatives.

2.7 EMEA Risk Management Strategy

Heads of national agencies in cooperation with the Agency agreed on the establishment of a European risk management strategy. The Agency proceeded as planned with regard to the development of the EMEA component of this risk management strategy. As part of this strategy, the mandate of the CPMP Pharmacovigilance Working party was reviewed. This resulted in an increase in frequency of meetings of the working party from 8 to 11 per year and the meeting schedule of the meetings was changed to coincide with the CPMP week of each month.

As part of the Agency’s component of the European risk management strategy the CPMP agreed on a revised handling of safety concerns for centrally processed applications, both pre- and post-authorisation. Once implemented, this procedure will allow for a pro-active conduct of pharmacovigilance, contributing to the concept of life-cycle management of medicinal products.

An important component is the involvement of specialised expertise in the CPMP activities. The CPMP endorsed nominations of some 92 experts at its November 2003 meeting who will form a pool to provide scientific support to the CPMP and rapporteurs. Areas of expertise include pharmacovigilance, epidemiology, biostatistics, methodology, clinical safety, vaccinology, advanced therapies and risk communication. Where appropriate, pharmaceutical companies will be encouraged to provide risk management plans addressing specific safety issues.
2.8 Arbitration and Community referrals

There was a significant increase in arbitration and Community referrals in 2003.

Referrals fall into 3 main categories:

- Referrals arising from the mutual recognition procedure for both initial applications (under Article 29 of the Community Code on medicines for human use) and post-authorisation variations (under Article 7(5) of Commission Regulation (EC) No 542/95) where there are disagreements between Member States
- Community interest referrals for safety-related issues (under Articles 31 and 36 of the Community Code)
- Referrals to harmonise within the European Union the conditions for medicines that are already authorised in the Member States, in particular with regard to their therapeutic indications (under Article 30 of the Community Code)

Details of all referrals are given in Annex 11.

Referrals to the CPMP now constitute a significant allocation of the Agency’s resources both in terms of scientific evaluation and discussion during CPMP plenary meetings. Approximately one-third of CPMP meeting time in 2003 was dedicated to consideration of arbitration and referral procedures.

Referral workload remained significant throughout 2003 with 2 ongoing referrals under Article 30 and 1 referral under Article 29 of Council Directive 2001/83/EC evaluated during the year. The CPMP issued 3 opinions for Article 30 procedures and 3 opinions for Article 29 procedures.

With respect to Community referrals under Article 31 of Council Directive 2001/83/EC the workload remained very high mainly due to the number of companies and marketing authorisations involved. The CPMP issued opinions for 4 Article 31 referral procedures.

The Agency managed the increasing workload in relation to these procedures, whilst adhering to the regulatory timeframes. Public information was made available once Commission Decisions were issued. In addition, internal working groups have reviewed the different aspects relating to arbitration and referral procedures, resulting in specific proposals to improve various aspects related to the management of such procedures. These proposals will be converted in 2004 in publicly available guidance documents.

2.9 Regulatory guidance

EMEA Post-Authorisation Guidance document

A first version of the EMEA post-authorisation guidance for centrally processed applications was developed. Once completed, this guidance document will provide companies with clarification on the interpretation of Community legislation on post-authorisation activities including the new variation legislation. It provides an overview of the EMEA position on issues, which are typically addressed in discussions or meetings with marketing authorisation holders in the post-authorisation phase. This guidance document currently addresses requirements on variations (type IA/IB and II) and extension applications.
2.10 Parallel distribution

The number of parallel distribution notifications was on target for 2003 with 389 initial notifications validated and 144 notifications of a change validated. The EMEA met with the Regulatory Affairs Sub-Group of the European Association of EuroPharmaceutical Companies (EAEPC) in July 2003 to develop process improvements, e.g. conduct of quality checks, labelling change notification process etc.

A further interested parties meeting was held with EAEPC in November 2003.

**EMEA policy on handling of conflicts of interests**

As part of the Agency’s continuous efforts to further improve its processes, a revision of the current handling of conflicts of interests for scientific committee members and experts was undertaken by the EMEA. This resulted in a revised policy that, with the agreement of the Management Board in December 2003, will enter into force as a pilot phase during the first quarter of 2004.

**Plasma master files (PMFs) and vaccine antigen master files (VAMFs)**

Guidelines on the data requirements and the proposed procedures for the processing of these new master files were developed in consultation with interested parties, including the European Commission and pharmaceutical industry. As a result of the consultation exercises, the guidelines and procedures were refined to allow implementation of the new facility afforded by the modifications to the legislation.

**Provision of CPMP scientific opinions to WHO**

Work begun on preparation of a procedure to provide CPMP scientific opinions in the context of cooperation with WHO, as foreseen in the ongoing review of pharmaceutical legislation. Draft guidelines on the data requirements and the proposed procedure will be put to interested parties for consultation and agreement, prior to implementation.

**Guideline on submission of marketing authorisation applications for pandemic influenza vaccines through the centralised procedure**

A guideline on a proposed procedure for the processing of marketing authorisation applications for pandemic influenza vaccines was developed in consultation with interested parties, including the European Commission and pharmaceutical industry. As a result of this consultation exercise and a workshop organised by the European Commission in November 2003, the guidelines and procedures were refined to allow implementation of the new facility afforded by the modifications to the legislation.
2.11 Working parties and ad hoc groups

**Biotechnology Working Party (BWP)**

The BWP met on nine occasions in 2003. In addition to the plenary meetings, it held a number of drafting groups to facilitate the development of positions papers on topics such as TSE, blood products, viral safety of biological/biotech products. The objectives are to provide on request of the CPMP a forum for discussion and harmonisation amongst quality and other experts to maintain and reinforce a uniform approach to the understanding of biotechnology and biological issues and to avoid and eliminate divergences in assessing biotechnology issues and interpreting biotechnology guidelines. The forum of the BWP facilitates the efficient use of European expertise on products, the provision of scientific advice and the generation of guidelines.

**Efficacy Working Party (EWP)**

The Efficacy Working Party met four times in 2003. Four therapeutic drafting groups have met as planned to support the Efficacy Working Party with very positive impact on the preparation of guidelines in cardiovascular, anti-infectives, CNS and pharmacokinetics.

The working party was responsible for preparing 26 guidelines of which four were new and 11 were published.

**Safety Working Party (SWP)**

The Safety Working Party met 3 times in 2003 and was in charge of 9 guidelines of which 4 were published and 5 are under discussion.

Two drafting groups supported the work of the Safety Working Party in the following areas: environmental risk assessment and risk assessment of medicinal products on human reproductive and developmental toxicities: from data to labelling.

**Pharmacovigilance Working Party (PhVWP)**

The PhVWP held 11 meetings in 2003 in the same weeks as the CPMP was holding its meetings, and herewith introduced their new meeting schedule that provided the opportunity for increased interaction between the CPMP and the PhVWP. In addition to the plenary, on average 5 drafting groups were held at the margins of each meeting on product-related issues, guidelines or organisational matters. Overall, 56 product-related issues were discussed at the request of the CPMP and 92 at the request of Member States.

Other activities of the PhVWP related to ongoing work on guidelines, contributions to the Notice to Applicants and to ICH. The PhVWP also held joint meetings with other working groups with regard to EudraVigilance and the implementation of the Clinical Trials Directive. Discussions were held with MRFG in relation to initiatives for improved interaction between the MRFG and the PhVWP and work sharing between Member States.

In relation to organisational matters, the PhVWP initiated in particular a review of new tools for Regulators for the purpose of information exchange and tracking of implementation and follow-up action. Moreover, the PhVWP provided contribution to the ongoing discussion on the EU risk management strategy. Part of this strategy was the revision of the PhVWP Mandate in September 2003, now reflecting in more detail their mission to provide advice on safety of medicinal products, investigate adverse drug reactions and to enable risk identification, assessment and management at any phase of the product life cycle.

**Herbal Medicinal Products Working Party (HMPWP)**

The Herbal Medicinal Products Working Party met 3 times in 2003 and welcomed the participation of additional observers from the Accession Countries. The Working Party adopted 3 core-data and prepared 4 new core-data after review of the corresponding monographs from ESCOP (European Scientific Cooperative on Phytotherapy). They also prepared 5 position papers concerning the use of herbal medicinal products containing various herbal substances (see Annex 10). A draft position paper on the biopharmaceutical characterisation of herbal medicinal products was prepared and the SOP on the recording of core-data was revised.

The working party also closely monitored the progress made at European Parliament, Council and Commission level on the proposal for a Directive on traditional herbal medicinal products, started preparatory discussions regarding Community herbal monographs and developed a draft structure for the future list of herbal substances, preparations and combinations with traditional indications.

**Organisational Matters Group (ORGAM)**

The ORGAM met 11 times in 2003 and addressed a wide variety of organisational topics aiming at further improving the EMEA processes in relation to human medicines as well as the functioning of the CPMP. The topics related to CPMP meeting
organisation (e.g. preparation for enlargement and improvement of the use of IT tools), the centralised procedure (e.g. establishment of therapeutic advisory groups, training of assessors, follow-up to the CPMP audit), pharmacovigilance-related issues (e.g. the handling of safety concerns by the CPMP, the revised mandate of the PhVWP, the implementation of EudraVigilance), and transparency and communication (e.g. establishment of the EMEA/CPMP Working Group with Patients Organisations, the 2003 performance indicators survey).

As part of a wider effort to streamline CPMP plenary meetings, the scope of the discussions within ORGAM has been extended since September 2003 to systematically include discussion on CPMP working party topics, mainly in the area of guideline development.

**EMEA/CPMP Working Group with patients’ organisations**

The EMEA/CPMP working group with patients’ organisations has been created as a result of the EMEA/CPMP workshop with patients’ organisations organised in 2002. The mandate of the group is to make proposals for action in the following areas in the context of the EMEA activities: pharmacovigilance, product information, dissemination of information/ transparency and interaction between the EMEA/CPMP and patients organisations. This group, which met three times in 2003, involves 8 European patients organisations.

**Invented name Review Group (NRG)**

The Invented Name Review Group (NRG) met 11 times in 2003 to review whether invented name(s) proposed by applicants for medicinal products would create public health concerns and more particularly potential safety risks. Collaboration with WHO in this field was increased resulting in a systematic participation by WHO in the review process. An interested parties meeting was held with EFPIA in April 2003 to review implementation of the revised guideline adopted in 2002 and process performance aspects. The NRG also welcomed observers from the accession countries to its meeting. In addition a retrospective review of invented names of centrally authorised products versus nationally authorised products in the accession countries was performed as part of the preparation for the EU enlargement.

A new tracking database became operational in 2003 to allow better monitoring of the review process.

The percentage acceptance rate for 2003 is 63 %, based on a total of 107 names reviewed, 67 names accepted, 40 names rejected and 13 names justified by applicants. The average timeframe to complete an invented name review was 39 days, which is in accordance with the guideline.

**Ad hoc Working group on (pre-) clinical comparability of biotechnology products**

This group met twice in 2003 and finalised an annex to the note for guidance on comparability of medicinal products containing biotechnology-derived proteins as drug substance.

**Paediatric Expert Group (PEG)**

The Paediatric Expert Group met five times in 2003 and issued two concept papers on renal system and immune system in the context of development of medicinal products for children. The group contributed to guidelines of the CPMP efficacy and quality working parties. The group was consulted by the EC on its proposals for a future paediatric regulation and was requested to prepare a preliminary list of priorities for studies on medicines for children’s use to be funded. The PEG liaised with EU paediatric learned societies in order to foster the necessary networking, particularly for clinical trials developments.

**Vaccine Expert Group (VEG)**

The VEG met on five occasions in 2003 including one meeting devoted to influenza pandemic. Plenary sessions are complemented by drafting groups addressing specific issues in a more focussed manner and generating positions papers on topics such as TSE, blood products, viral safety of biological or biotech products. The VEG prepared guidelines on the data and dossier requirements necessary in the event of influenza pandemic in consultation with the European Commission and vaccine manufacturers.

**Blood Products Working Group (BPWG)**

The BPWG met on four occasions in 2003 including two times as specialist drafting groups.

**Ad hoc Expert group on cell therapy**

The group met twice in 2003. In consultation with the other CPMP and CVMP working parties, the ad hoc group completed the revision of a concept paper on xenogeneic cell therapy that was adopted by the CPMP and CVMP in December 2003.
Ad hoc Group on gene therapy

During its two meetings in 2003, the group contributed to a BWP position paper related to lentiviral sectors and discussed topics including insertional mutagenesis and oncogenesis, gonadal signalling and germ-line integration study in order to prepare for the second ICH workshop on gene therapy held in November 2003 as a satellite session of the of the ICH 6 Conference, in Japan. The two scientific meeting reports and the ICH gene therapy workshop communication paper were published by the EMEA.

Ad hoc Group on pharmacogenetics

This group met three times in 2003. The group finalised the English version of the CPMP position paper on terminology in pharmacogenetics in lay language, ahead of its translation into all official EU languages. The Pharmacogenetics expert group finalised a concept paper on Pharmacogenetics briefing sessions, published in January 2003 and participated to three briefing session with companies where pharmacogenetics-specific issues were discussed under the ‘safe harbour’ concept.

Ad hoc groups on Chemical Threats

At the request of the European Commission, in the framework of action Programme of Cooperation on Preparedness and Response to Biological and Chemical attacks (BITCHAT), the EMEA established a CPMP expert group responsible for drafting a guidance document on medicinal products to be used in the framework of chemical threats. The EMEA guideline was released on 13 May 2003.

2.12 Enlargement and international activities

Major efforts were made in 2003 to allow for a smooth transition for the new Members States in May 2004. Considerable resources were allocated into the PERF III programme and specific training was provided to assessors from accessing countries in order to allow familiarisation with the European procedures.

International activities focussed on involvement in ICH and collaboration with non-EU national competent authorities. The EMEA contributed to the ICH process through the provision of technical coordination and scientific support through its scientific committee and working parties. In 2003 three meetings were organised, one in Europe and two in Japan, the last meeting being followed by the ICH-6 conference and satellite sessions. The EMEA contributed directly to such activities.

The EU and the US Food and Drug Administration (FDA) concluded a confidentiality arrangement that provides a framework for regulatory cooperation. Preparations for an implementation plan were begun. Cooperation with the FDA in 2003 mainly focussed on regular videoconferences in the field of pharmacovigilance.

In addition, considerable progress was made in the field of scientific advice. The CPMP Scientific Advice Working Group held a first videoconference with the FDA as a pilot phase for parallel advice given by the Agency and the US FDA authorities on an orphan medicinal product.

Other examples of international cooperation related to visiting expert programmes with the Canadian and Chinese Health Authorities.

2.13 Mutual recognition facilitation group

The Mutual Recognition Facilitation Group (MRFG) reports to the heads of national authorities for human medicines.

The MRFG is made up of delegates from the EU, Iceland and Norway who meet at the EMEA to coordinate Member States’ positions on topics related to the mutual recognition procedure. Observers from the accession countries and European Commission also participate in the monthly meetings.
The MRFG provides procedural and regulatory advice on request and develops general guidance papers, which are published on the MRFG website.

The MRFG met eleven times in 2003. Julia Yotaki chaired the meetings during the Greek presidency in the first half of 2003 and Silvia Fabiani during the Italian presidency in the second half of the year. Press releases with statistics and adopted documents are published monthly on the Heads of Agencies website. Two informal meetings were held in 2003, in Athens and Rome.

The future enlargement of the European Union was a permanent item on the MRFG agenda. In addition, the MRFG continued to answer questions from the pharmaceutical industry and develop new guidance papers to assist marketing authorisation holders and national competent authorities. Existing guidance documents were updated in accordance with new Community legislation.

A number of MRFG subgroups met in 2003. The Joint CPMP/MRFG working group on harmonisation of SPCs, created in 2001 under a mandate given by the Heads of Agencies, met 4 times in 2003. The CTS/Eudratrack subgroup, dealing with the mutual recognition procedures’ tracking system, met 5 times in 2003. On 1 October 2003, after the new variations regulation entered into force, a new CTS/Eudratrack client was released, taking into account the new type IA and IB variations. The group is now working in close contact with DIMDI/BfArM to test and improve the client in view of the final reengineering, foreseen in May 2004.

The joint Pharmacovigilance Working Party/MRFG working group met 3 times in 2003, the main aims of this group being to improve cooperation between the Pharmacovigilance Working Party and MRFG in risk management, to harmonise the birthdates of PSURs, to share work in the field of PSUR assessment and to improve the format and quality of PSURs.

The EMEA supported the chairpersons, the MRFG and the subgroups in their activities. This support included the organisation of two preparatory meetings for the hand-over of the presidency.

The subgroup looking at preparations for implementation of new Community legislation, in particular concerning the establishment of the Coordination Group, met twice in September and October 2003, in Lisbon and Rome respectively. A document was drafted and submitted to Heads of Agencies for consideration at their meeting in November 2003. This document addresses the function and the role of the future coordination group, and the support the EMEA should provide to such coordination group.

The number of new applications finalised in 2003 increased compared to 2002. In addition, there was an increase in the number of arbitrations compared to previous years. Statistical information on applications under the mutual recognition procedure is provided by the EMEA and presented in the monthly MRFG press releases.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>New applications</td>
<td>620</td>
<td>135</td>
<td>529</td>
<td>5</td>
</tr>
<tr>
<td>Type I variations</td>
<td>2,326</td>
<td>107</td>
<td>2,473</td>
<td>N/A</td>
</tr>
<tr>
<td>Type IA variations</td>
<td>434</td>
<td>92</td>
<td>230</td>
<td>N/A</td>
</tr>
<tr>
<td>Type IB variations</td>
<td>257</td>
<td>93</td>
<td>94</td>
<td>N/A</td>
</tr>
<tr>
<td>Type II variations</td>
<td>1,091</td>
<td>232</td>
<td>754</td>
<td>3</td>
</tr>
</tbody>
</table>

*The numbers include multiple procedures as stated at 31 December 2003.
Chapter 3
Veterinary medicines

Overview

Unit for the Veterinary medicines and inspections

Head of Unit
Peter JONES

Head of Sector for veterinary marketing authorisation procedures
Jill ASHLEY-SMITH

Deputy Head of Sector for veterinary marketing authorisation procedures
Melanie LEIVERS

Head of Sector for safety of veterinary medicines
Kornelia GREIN

Head of Sector for inspections
Emer COOKE

The annual report for inspection activities is given in Chapter 4.

For Committee members, working parties and ad hoc groups, see Annex 3.

Priorities for veterinary medicines in 2003 – progress report

• The definition of EU standards for electronic reporting has been progressed and preparation of all the elements to bring EudraVigilance to full operational release and implementation is close to being finalised

• The Agency and CVMP have made further significant progress in advancing initiatives to facilitate better provision of medicines for minor uses and minor species. In particular, further extrapolation of major species MRLs to minor species has been achieved and the CVMP issued a landmark consultation paper in June 2003 setting out its strategy for a minor uses and minor species (MUMS) policy

• The Pharmacovigilance Working Party succeeded in meeting some of the goals agreed to by the Committee in promoting veterinary pharmacovigilance in the EU, by having finalised a common reporting form and drafted guidelines on, mechanisms to trigger investigations on safety of medicines and on causality assessment

• In response to requests from heads of veterinary medicines agencies, the EMEA developed a concept paper to be completed by working parties, subsequently adopted by CVMP, to set out a business case/impact analysis prior to work on any new guideline/position paper being initiated; this enables consultation by interested parties and Member States on the guidelines in question

• Considerable effort in supporting the accession countries in their preparation for enlargement has met with particular success in the veterinary sectors within the PERF programme. A number of workshops on various disciplines resulted in many of the outstanding issues being addressed and the PERF III veterinary mini-conference held in Warsaw was very successful in meeting the objectives set

• Despite encouragement to prospective applicants through the centralised procedure to request scientific advice from the CVMP in the pre-development phase, the uptake of this service continued to be slow in the veterinary area and discussions are ongoing with industry to clarify where difficulties may exist

• The Immunologicals Working Party addressed two critical issues in 2003. The first was an annex was prepared to the Note for guidance on requirements and controls applied to Bovine Serum to aim to control contamination with Bovine Viral diarrhoea virus. The second was a paper on data requirements for removing target animal batch safety test as final product testing in the EU
3.1 Scientific advice

Even though applicants are more aware of this provision, the growth in submissions requesting such advice was slower than expected. Industry have reported that some elements in the procedure are discouraging potential applicants and discussions are ongoing on these issues to try and address the matters of concern.

3.2 Initial evaluation

The total of 10 centralised applications were received in 2003, in line with forecasts. A significant number of letters of intent for applications to be submitted in the first half of 2004 were also received in the last quarter of 2003. The number of applications to establish new maximum residue limit fell short of forecasts.

All applications were processed within the regulatory deadlines. Most EPARs were also published in a timely manner following publication of the Commission marketing authorisation decision.
The third report of the joint EMEA-industry survey of the centralised procedure for veterinary medicinal products covering 12 applications was published in 2003.

As the number of applications continues to grow there is a greater familiarity with procedures, which was reflected in the results showing a high level of satisfaction with the procedure overall with some clear improvements evident since the last survey.

The survey indicated that rapporteurs and co-rapporteurs continued to have concerns about the quality of the safety and efficacy dossiers in some of the submissions reflecting that a number of the applications might have been submitted somewhat prematurely. The results of the survey were presented at the Infoday with interested parties on 14 November 2003.

3.3 Availability of medicines

The ongoing concern regarding the provision of sufficient veterinary medicinal products for use by practitioners in minor uses and minor species has again stimulated considerable effort by EMEA and CVMP in this reporting year to achieve further progress to try and find solutions to the problem with regular and detailed consultation with Member States and interested parties.

Continued progress was achieved in extrapolating major species MRLs to minor uses particularly for those substances in cattle, to goats and sheep (10 substances), especially for milk-producing animals. In addition, extensions were made for four substances in Annex II to all food producing species (acetylsalicylic acid, sodium acetylsalicylate, acetyl acid DL-lysine and carbasalate calcium) and for one substance in Annex I (emamectin) from salmonidae to fin fish.

All parties agreed that a piecemeal approach to this problem will not provide the answers and with this in mind, the Committee at its June meeting adopted for consultation a position paper detailing a strategy for a minor uses and minor species policy, taking a holistic approach to the subject for both biologicals and pharmaceuticals and detailing proposals for the short, medium and long-term.

The commitment of the Agency to support and drive this programme forward is underpinned by the decision of the Management Board, at its October 2003 meeting, to approve one of the key short-term recommendations in the paper to
3.5 Post-authorisation activities

Post-authorisation activities in respect of centrally approved veterinary medicines were much as forecasted with the exception that the number of extensions to market authorisations (2) were fewer than expected (8). The trends were similar to previous years compatible with the growth in products authorised.

Extensions and modifications to existing MRLs were below the forecast.

3.4 Establishment of maximum residue limits for old substances

Of the 8 old substances that were remaining in Annex II of Council Regulation (EC) No 2377/90, CVMP has concluded the evaluation of 5 of them following the receipt of additional data from applicants, 4 of which have been proposed for inclusion in Annex I of Council Regulation (EC) No 2377/90 and one for Annex II. These include:

- Alphacypermethrin
- Cypermethrin
- Kanamycin
- Metamizole
- Morantel

Responses are awaited from the sponsor in respect of the substance altrenogest, and two substances flugesterone acetate and norgestomet, although recommended for inclusion by CVMP in Annex II, have been given provisional status in Annex III with expiry in 2008.
3.6 Pharmacovigilance and maintenance activities

Considerable progress has been achieved in meeting the challenges identified at the beginning of the reporting period as key issues needing to be addressed during 2003. They include:

- EudraVigilance in the veterinary sector was advanced with the release of EudraVigilance Veterinary 2.0, as well as the adoption of the CVMP guideline on data elements for electronic submission of adverse reaction reports (CVMP/065/03), which includes message and transmission specification. Testing of the web-based reporting tool is well underway with good collaboration from Member State competent authorities and marketing authorisation holders. Significant progress was also made to complete the controlled terminology required for EudraVigilance Veterinary.

- Further efforts have continued to resolve differences between the parties at VICH on harmonisation of pharmacovigilance reporting, but a successful outcome has yet to be achieved and some significant hurdles remain.

- In support of various initiatives supported by CVMP to promote pharmacovigilance in EU, a number of guidelines on topics agreed to by the Committee and its interested parties have been finalised and released for consultation (see report under Pharmacovigilance Working Party) and preparation is well underway to publish pharmacovigilance bulletin reports on products having a Community authorisation. Significant progress was made on the update and revision of the general guideline on pharmacovigilance of veterinary medicinal products on (EMEA/CVMP/183/96) and a new guideline on mechanisms to trigger investigations of the safety of veterinary medicinal products was also progressed.

- A total of 43 periodic safety update reports were received – the majority on time, and subsequently processed in a timely manner. No change to the risk benefit of any product was called for.

- It is worthy of note that, with one exception, for no centrally authorised product was it considered necessary to change the risk benefit summary underpinning the scientific opinion with consequent changes to the SPC and label.

3.7 Arbitration and Community referrals

There was no significant increase in this activity, with one referral received on the grounds of safety related to potential inadequacy of the withdrawal period of Eprinex Pour-on (eprinomectin).
3.8 Regulatory guidance

Interested parties

The EMEA has continued to build on its relationship with the interested parties to the CVMP with numerous opportunities for dialogue and exchange of views being organised during the year which include:

- Focus groups with industry technical experts between CVMP chair and vice-chair, EMEA secretariat and chairs of CVMP working parties to review the work programmes in 2003 for the CVMP working parties and to receive industry comments on the issues being addressed under the various initiatives

- Regular bilateral meetings were held between the European industry federation, IFAH-Europe, and the secretariat of the Agency to exchange views on matters of current topical interest

The EMEA continues to jointly organise Infodays with the interested parties, the last one being in November, where the two major topics, availability of medicines – MUMS policy and antimicrobial resistance were the subjects for discussion.

Working parties and ad hoc groups

Each working party had undertaken a review of its mandate and continues to plan its activities so that once again the extensive work plans for 2004 were considered in some detail and adopted by CVMP.

The CVMP is reflecting on its next moves in continuing its risk management strategic plan to minimise antimicrobial resistance in the veterinary sector has agreed to create a scientific advisory group to advice the Committee on its future activities in this context and to undertake evaluation of technical issues and questions as they arise.

3.9 Enlargement and international activities

The EMEA and CVMP continue its active involvement in international affairs on various issues.

Continued coordination of the scientific input of the EU regulatory authorities into VICH, where four guidelines have been progressed to the consultation step or finalised.

Scientific expertise in support of 13th CCRVDF meeting of Codex Alimentarius and input into the CCRVDF working parties on antimicrobial resistance and on risk management methodologies in respect to residues from veterinary drugs in food.

Support to FAO/IAEA workshop on strengthening capacities for implementing Codex standards regarding veterinary medicines in developing countries.

The EMEA and IFAH jointly chaired the first global International Animal Health Conference held in Nice, which addressed a wide variety of topics in relation to veterinary medicine. The conference attracted participation from many countries throughout the world and was considered to have been a considerable success by speakers and participants alike.

The culmination of another 18 months work undertaken in 6 workshops on a wide variety of topics under the third phase of the PERF programme was the PERF veterinary conference held in Warsaw. This conference for producers and users of veterinary medicines in the accession countries provided a forum for addressing many of the outstanding issues and planned activities prior to enlargement of the European Union on 1 May 2004.

The Veterinary medicines unit secretariat continues to work with heads of national veterinary medicines agencies through the HEVRA forum.
3.10 Veterinary mutual recognition facilitation group

The Veterinary Mutual Recognition Facilitation Group (VMRFG) met once a month (except August) in 2003, at the EMEA under the Chairmanship of the Greek and the Italian presidencies respectively. The group changed their meeting days to Thursdays and Fridays of the CVMP week from June 2003, moving from one day to a two-day meeting. The EMEA provided secretariat and administrative support to the group. Observers from veterinary authorities of central and eastern European countries (CAVDRI) as well as the three EEA-EFTA countries participated in plenary sessions. Two informal meetings were held in 2003 – one in Athens in May under the Greek presidency and one in Rome in November under the Italian Presidency.

The number of mutual recognition procedures completed in 2003 was 88. Nine Member States acted as the reference Member State in mutual recognition procedures in 2003, compared to ten in 2002. During this year, some of the central and eastern European countries (CAVDRI) have been involved in the simplified mutual recognition procedures (9 % of the procedures).

In 2003, VMRFG provided answers to a wide range of questions from both Member States and industry on a number of different issues. The group also adopted a number of documents related to the management of procedures. The summary report of the reasons for withdrawals in 2002 was published on the HEVRA website.

The VMRFG interested parties liaison group met three times (January, June and October) during 2003. The group consisted of representatives from VMRFG, IFAH Europe and from the European Generic Association (EGGVP). The joint VMRFG-IFAH Europe survey of the mutual recognition procedure in 2002 was published on the HEVRA website and was continued in 2003. A report on the activities of the VMRFG was provided at each CVMP meeting in 2003. The chairperson provided a report both to HEVRA (Athens, Rome) and to the Veterinary Pharmaceutical Committee (Brussels) during their meetings.

Useful web site:
Heads of agencies for medicines for veterinary use
http://www.hevra.org

In 2003, VMRFG provided answers to a wide range of questions from both Member States and industry on a number of different issues. The group also adopted a number of documents related to the management of procedures. The summary report of the reasons for withdrawals in 2002 was published on the HEVRA website.

The VMRFG interested parties liaison group met three times (January, June and October) during 2003. The group consisted of representatives from VMRFG, IFAH Europe and from the European Generic Association (EGGVP). The joint VMRFG-IFAH Europe survey of the mutual recognition procedure in 2002 was published on the HEVRA website and was continued in 2003. A report on the activities of the VMRFG was provided at each CVMP meeting in 2003. The chairperson provided a report both to HEVRA (Athens, Rome) and to the Veterinary Pharmaceutical Committee (Brussels) during their meetings.
Chapter 4
Inspections

Overview

Head of Sector
Emer COOKE

Working parties and ad hoc groups
ad hoc Meeting of GMP inspection services
Emer Cooke (chair)
ad hoc Meeting of GCP inspection services
Fergus Sweeney (chair)

Of the priorities identified for 2003, the sector’s contribution to the PERF III programme was particularly successful.

- Three GMP workshops were held as part of the PERF III programme, focussing on quality systems, tabletting and practical inspection aspects respectively. Eight joint inspections involving EU inspectors and inspectors from accession countries were also organised

- An important seminar to review progress and experience with the sampling and testing programme was held in EMEA in September 2003, providing important input into improving efficiency of future programmes

- The EU-Canada agreement entered into force on 1 February 2003. The MRA with Japan could not be completed by June 2003 as originally anticipated and preparatory work continued throughout the year. No progress was made on the MRA with the USA during 2003. All other MRAs are operating successful and being closely monitored

- Progress on implementation aspects of the EU clinical trials directive accelerated, with the finalisation of guidance documents foreseen in the directive. Implementation of this has also begun with particular focus on the establishment of a simpler clinical trial database (EudraCT) than originally planned and the integration of the database on suspected unexpected serious adverse reactions (SUSAR) into the Eudravigilance database

- Processing of all inspections proceeded efficiently and within the legal timeframe with those for GMP exceeding the forecasted number and those for good clinical practice (GCP) falling below. The certificate scheme for centrally approved products continued successfully and efficiently in response to over 700 requests for certificates from marketing authorisation holders

- A total of 20 quality defects were successfully coordinated by the EMEA during 2003, resulting in 4 recalls of affected batches of centrally authorised products

- Representatives of accession countries participated actively in the harmonisation work of the EMEA on GMP and GCP through participation in the meetings of the ad hoc group of inspectors on good manufacturing practice (GMP) and good clinical practice (GCP)
4.1 Inspections

Good manufacturing practice activities

Requests for good manufacturing practice (GMP) inspections exceeded forecasts, mainly due to an increasing focus on the organisation of inspections, providing an important contribution to both the pre- and post-approval monitoring of medicinal products in the human and veterinary medicines fields.

The ad hoc group of GMP inspection services met four times in 2003, and finalised a revision to Annex 1 to the EU GMP guide. Annex 13 of the GMP Guide was published in July. Significant progress was made on several proposed new additions to the GMP guide and a position statement agreed on the professional discretion used by qualified persons releasing products that are not in full compliance with the marketing authorisation. In addition a guideline for inspectors on quality systems was completed. Significant efforts to integrate accession country representatives into the GMP related activities of EMEA were made.

Two joint sessions with the CPMP/CVMP Quality Working Party were held in order to address inspection and assessment implications of aspects of process analytical technology techniques as well as ways of improving the monitoring of ongoing quality of marketed medicinal products.

Significant input into the ICH initiative on GMP and quality systems was also provided, building on FDA initiative for “Good manufacturing practices for the 21st century”.

The year 2003 saw the successful completion of the pilot phase of a joint audit programme to assess the GMP compliance system of Member States in view of harmonising and improving the performance of European inspection services. The experience gained has allowed the development of a simplified scheme making the best use of other similar activities underway.

An apparent decrease in a number of quality related defects for centrally authorised products was noted in the first quarter of 2002 with only two quality defects received by the EMEA, resulting in the recall of affected batches of one centrally authorised product. A total of 15 defect reports were handled during the second quarter leading to three recalls of affected batches. The majority of the quality defects observer were classified as class III (minor) and related to packaging material defects (rubber particles, broken vials, leakages, etc) and labelling problems (e.g., wrong strength, wrong bar code, etc).

Progress on the GMP database developed by the EMEA in 1999 continued during 2003, in particular extending its application to other good practices, including data from GCP, GLP and pharmacovigilance inspections.

This database was originally developed to provide a management tool for GMP inspections of centrally authorised products. In 2003, it was made accessible through the web to all EEA Member States and is now being extended to a multi-user application, allowing write-access.

Good laboratory practice activities

No good laboratory practice (GLP) inspections were requested in 2003.

Agreement was reached on a number of procedural documents at the final meeting of the ad hoc GLP working group held in October 2003.

- Procedure/SOP for requesting and reporting GLP inspections under the centralised procedure
- Format for GLP reports under the centralised procedure
- Contract between EMEA and inspecting authority for GLP inspections

Good clinical practice activities

The number of good clinical practice (GCP) inspections for human medicinal products requested, decreased significantly in 2003. This decrease reflects resource constraints at Member State level as authorities focus their resources on implementing the clinical trials directive nationally, in addition to the effect of the lower number of centralised applications received last year.

About half of the inspections requested were conducted post-authorisation on pharmacovigilance activities. This reflects the growing emphasis of European regulators on ensuring compliance of marketing authorisation holders with their pharmacovigilance obligations.

The ad hoc group of GCP inspection services met five times in 2003, one of these meetings taking the form of an off-site training session for new and experienced GCP inspectors, including inspectors from accession countries as well as EU, EEA and Switzerland. The majority of its work in 2003 has been focussed on further harmonisation activities in relation to the conduct of inspections and interpretation of GCP and pharmacovigilance data.
In addition the group has worked closely with the Mutual Recognition Facilitation Group on approaches to the assessment and inspection of the clinical investigation of bioequivalence studies of generic products. This collaboration is an important element to assure the quality of these studies.

Work has been initiated on the preparation of guidance on the use of computers in clinical trials, on inspection of phase I trials, as well as continued development of clinical trial product safety/post-marketing pharmacovigilance inspection guidance.

Procedures developed for the GCP of clinical trials in the centralised procedure applications include those for:

- Coordination of inspections
- Preparation of inspections
- Reporting of inspection
- Inspection records
- Sponsor/CRO, investigator, laboratory inspections, which were reviewed and updated during the year.

No GCP inspections for veterinary medicinal products have yet taken place.

---

### 4.2 Mutual recognition agreements

The European Commission – Canada agreement entered into force on 1 February 2003 following successful completion of all outstanding tasks. The operational phase started with an exchange of certificates of GMP compliance of a manufacturer between the Canadian and EU authorities.

The preparatory phase of the mutual recognition agreements (MRA) with Japan encountered some delays and was not completed by June 2003 as originally anticipated. Mutual visits and preparation of documents continued throughout 2003 to progress the work.

Preparation for enlargement also included the area of MRA. The European Commission – Australia, New Zealand, Switzerland MRAs will automatically extend to the new Member States. For the Canadian agreement, a new round of evaluation visits will be carried out by Health Canada and preparation of GMP inspectorates of accession countries for these visits began at the end of the year.

---

### Mutual recognition agreement (MRA) implementation status and coverage

<table>
<thead>
<tr>
<th>MRA</th>
<th>Implementation status</th>
<th>Coverage</th>
</tr>
</thead>
<tbody>
<tr>
<td>European Commission – Australia</td>
<td>Human medicinal products: 1 January 1999</td>
<td>Human and veterinary medicinal products</td>
</tr>
<tr>
<td></td>
<td>Veterinary medicinal products: 1 June 2001</td>
<td>Official batch release excluded</td>
</tr>
<tr>
<td>European Commission – Canada</td>
<td>Operational since 1 February 2003</td>
<td>Human and veterinary medicinal products</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Veterinary immunologicals and vaccines</td>
</tr>
<tr>
<td></td>
<td></td>
<td>excluded</td>
</tr>
<tr>
<td></td>
<td>Extended indefinitely to allow work to be completed.</td>
<td>Currently excludes active substances, investigational medicinal products, medicinal gases</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Official batch release excluded</td>
</tr>
<tr>
<td>European Commission – New Zealand</td>
<td>Human medicinal products: 1 January 1999</td>
<td>Human and veterinary medicinal products</td>
</tr>
<tr>
<td></td>
<td>Veterinary medicinal products: 1 June 2002</td>
<td>Official batch release excluded</td>
</tr>
<tr>
<td>European Commission – Switzerland</td>
<td>1 June 2002</td>
<td>Human and veterinary medicinal products</td>
</tr>
<tr>
<td></td>
<td></td>
<td>recognition of official batch control of biologicals</td>
</tr>
<tr>
<td>European Commission – United States</td>
<td>Not in operation. Transitional period ended.</td>
<td>Human and veterinary medicinal products</td>
</tr>
<tr>
<td></td>
<td>No decision on formal extension of the transitional period has been taken.</td>
<td>Official batch release excluded</td>
</tr>
</tbody>
</table>
4.3 Certificates of a medicinal product

The revision of the administrative charge at the end of 2002 has had the expected effect of encouraging companies to streamline their requests for certificates thus moderating the number of requests and consequently the administrative work on the side of the EMEA. Reflecting the new arrangements, the demand for certificates was unstable during 2003, with higher requests seen in the first half of the year but significantly lower demand during the second half of the year.

4.4 Implementation of the clinical trials directive

Preparations for the implementation of Directive 2001/20/EC on the conduct of clinical trials continued in 2003. The GMP inspectors’ group started work on a concept paper for GMP for investigational medicinal products used in gene and cell therapy and prepared modifications to the batch certificate and GMP certificate forms to reflect the possibility of including investigational medicinal products.

The harmonisation and training activities of the GCP inspectors’ group are fundamental to the mutual recognition of GCP inspections between member states.

EMEA continued to participate actively in the European Commission working party on the preparation of other documents needed under the Directive, in particular, as rapporteur for the guidance documents on the European database on clinical trials (EudraCT) and on the European database of SUSARs (Eudravigilance clinical trial module). The texts of these guidance documents were finalised and published in July 2003.

In addition EMEA has drafted design and specification documents and begun work on the projects to implement the clinical trial database and the clinical trial part of the EudraVigilance database. As part of this work, the EMEA provided support to the first two Technical Implementation Groups on the EudraCT database, chaired by Spain in the third quarter of 2003.

4.5 Sampling and testing

Monitoring of centrally authorised medicinal products is performed by the Network of Official Medicines Control Laboratories. The activities of the network are coordinated by the European Directorate of the Quality of Medicines (EDQM) and the EMEA. The 2003 testing programme was implemented for 38 centrally authorised products.

A seminar involving all stakeholders in the programme was organised in the EMEA in September 2003. Over 50 participants attended from national competent authorities, official control laboratories, inspectorates, accession countries and industry. This was an important occasion, providing the first opportunity since the launch of the programme in 1999 for all partners to have an open discussion and provide feedback on current processes. The issues raised during discussion will be addressed in an action plan and be reflected as changes to subsequent programmes.
Chapter 5
EU telematics strategy

The direction of the implementation of the EU telematics strategy during 2003 was changed following a meeting of the Telematics Steering Committee in Verona in July 2003. The strategy changed from a sequential approach involving beginning and completing a small number of projects before embarking upon a second wave, to a slower implementation across the whole spectrum of projects.

The achievements during 2003 have been as follows:

<table>
<thead>
<tr>
<th>Initiatives</th>
<th>Achievements</th>
</tr>
</thead>
<tbody>
<tr>
<td>EudraNet</td>
<td>The EMEA successfully assumed responsibility for the service with effect from 1 January 2003. EudraLink was successfully launched in January 2003. Take-up has been good, and the service now has approximately 1600 registered users from the regulatory authorities and other stakeholders in the regulatory system. A project to define and implement a security infrastructure that meets the requirements of all the stakeholders in the regulatory system and which will be common to all Eudra systems has been initiated. The requirements gathering exercise, together with analysis thereof, has been completed. Testing of an IP/VPN infrastructure in comparison with the service using the existing structure has been completed during the year. EudraWorkSpace has been installed in pilot form at the Agency. The form and extent of its deployment is currently being reviewed.</td>
</tr>
<tr>
<td>EuroPharm</td>
<td>Agreement on a pan-European reference data model is nearly complete. The reference data model will need to be extended as work on EuroPharm over its entire scope progresses. A limited prototype has been built for demonstration to interested parties over the early part of 2004. A contract for the specification of the system was put in place.</td>
</tr>
<tr>
<td>EudraVigilance</td>
<td>The principal achievement during the year was to extend the system to include reports relating to medicinal products for veterinary use.</td>
</tr>
</tbody>
</table>

Cont...
<table>
<thead>
<tr>
<th>Initiatives</th>
<th>Achievements</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic submission</td>
<td>The first phase of the implementation of the electronic common technical document (eCTD) at the EMEA is complete, and the first full submission using the eCTD (in parallel with the paper submission) has been received and processed. One variation has also been received in eCTD format and processed, again in parallel with the paper submission. A contract for a review solution that is available for all competent authorities in the EU is in place, and the system is installed at the EMEA and two of the national competent authorities. The system is being used to refine the reviewers’ requirements over 2004. The Product Information Management (PIM) proof of concept was completed, and further work on the exchange standard, based on the proof of concept experience, was carried out. A contract for the specification of a system for the Agencies was put in place.</td>
</tr>
<tr>
<td>Clinical trials databases</td>
<td>Both the clinical trials database and the EudraVigilance clinical trials module were specified, and contractors started work on developing the two databases.</td>
</tr>
<tr>
<td>Infrastructure</td>
<td>Projects have been accompanied with appropriate infrastructure. Work on defining the architecture underlying, and binding together, the collection of Eudra projects is complete. Project management staffing has been increased over 2003 to provide appropriate resources to take the projects forward in 2004. This situation was only achieved in the third and fourth quarters of 2003.</td>
</tr>
</tbody>
</table>
Chapter 6
Support activities

6.1 Administration

The following specific objectives were achieved and projects carried out in 2003:

- Introduction of the new financial regulation, with revision of related procedures
- Continuous information to staff on the proposed new staff regulation and participation in preparatory conferences with the European Commission
- Further development of the computer-based personnel data and management system
- Development of an improved activity based budgeting database and budgetary planning
- Participation in the preparation of a concept for a new legislative base for the future financing of the agency
- Preparation for refurbishment of the 4th, 5th and 8th floor to accommodate new staff, the telematics projects and delegates and experts from the new member states; refurbishment of 8th floor was practically accomplished in 2003
- Expansion of the training programme and development of a competence development scheme for all staff
- Preparation of new and modified accounting practices in line with the reform of the EU accounting system

Personnel and budget

The principal objectives of the Personnel and Budget Sector are the development and timely and accurate management of EMEA human and financial resources, including recruitment procedures and professional training, as well as the provision of information to staff and other concerned persons on these matters. All the above objectives were achieved and further developed with a view to the specific projects mentioned below.

Specific Projects

- The new Financial Regulation with revision of procedures and staff training was successfully introduced and implemented
- The system of activity based budgeting was further developed and refined as well as adapted to the specific work environment of the agency
- An expanded professional training programme directed towards a continuous system of competence development was set up and will be put into practice in the coming year
- The 2003 budget was successfully implemented through regular monitoring, regular contacts and meetings with the scientific units and the European Commission and continuous and cautious adaptations through transfers and one amending budget; principles of sound financial management were applied
- The 2004 draft budget was reviewed as compared to the preliminary draft budget of February 2003 and the 2005 preliminary draft budget was prepared
- Contacts were established with the budgetary authority for the 2002 discharge procedure
- Together with the scientific units a harmonised system for the financial processing of fees was set up and successfully introduced
- Following a thorough preparatory phase an internal policy for part-time working was introduced respecting the prerogatives of the staff regulations on the one side and the specific work environment of the EMEA on the other
- The policy for movement between categories was introduced and successfully applied
- A set of guidelines for a “family friendly policy” has been set up and implemented successfully
Specific Objectives

- Internal procedures were improved with regard to the cooperation with the operational sectors and by external communication with pharmaceutical companies
- The customer accounting module was developed as planned
- Si2/SAGE/Lloydslink integration
- This project has been accelerated on completion of the Si2 upgrade in 2002. The Si2 /Lloydslink Bulkload interface was completed and is fully operational
- The Accounts Sector contributed where appropriate to the drafting of the new financial regulation, which was implemented from 1 July 2003
- The new version of Si2 complying with the new financial regulation was installed in August
- The ActiTrak system for the cost analysis of EMEA staff and activities has been revised and overhauled both to reflect a changed pattern of activity and to support the activity based budgeting as an instrument for planning
- Cooperation with the Court of Auditors for the 2002 budget was successfully conducted

Accounts

General Objectives

- To maintain the accounts, make payments and collect revenue in accordance with the procedures laid down in the financial regulation
- Overall this objective is achieved and no significant matters have been raised by either internal or external audits
- To manage efficiently the cash resources of the agency including the relationship with the agency's banks
- By use of the forward contract facility Euros were sold forward to purchase pounds whenever the rate was significantly above the budget rate. This activity is carried out in accordance with the approved EMEA policy. The EMEA’s Sterling needs are covered through the end of June 2004
- To provide accurate, timely financial information to management
- The timeliness of the budgetary accounting reporting slipped in the earlier months. This has been addressed and specific deadlines have been put in place
**Workload**

**Workload volumes - totals**

<table>
<thead>
<tr>
<th>Year</th>
<th>Number of payments received</th>
<th>Number of payments made</th>
</tr>
</thead>
<tbody>
<tr>
<td>2001</td>
<td>1,775</td>
<td>2,041</td>
</tr>
<tr>
<td>2002</td>
<td>10,399</td>
<td>11,136</td>
</tr>
<tr>
<td>2003</td>
<td>17,639</td>
<td>18,476</td>
</tr>
</tbody>
</table>

**Cumulative situation on fees (money in)**

- Jan-Feb-Mar-Apr-May-Jun-Jul-Aug-Sep-Oct-Nov-Dec
- 2001: 0
- 2002: 20,000,000
- 2003: 40,000,000

**Infrastructure services**

**Specific Objectives:**

- In preparation for the ten new Member States a tender was launched for the refurbishment of the 4th floor to increase the number of offices for the delegations.

- Business continuity planning and disaster recovery. The business continuity plan was completed and all Units and Sectors prepared telephone cascades. A tender for a business continuity supplier to provide the EMEA with a disaster recovery site were prepared. A disaster recovery company has been identified to manage the telephone calls to the Agency for contingency purposes.

- The function of a contract manager was introduced at the end of 2003. The contract manager will have a horizontal function in that she will be responsible for the supervision, organisation and conclusion of EMEA contracts with third parties.

- Acquisition of additional office space. This year has seen the acquisition of the 8th floor of 7 Westferry Circus and the consequent publication of a tender for the fitting out of this floor with offices, IT training room and a computer room.

- Award of contract for off-site archiving. A new contract was awarded for off-site archiving and ISERV oversaw the move of all the archive storage boxes to the new location.

**Reception - visitors to the agency**

- 2001: 17,895
- 2002: 18,539
- 2003: 18,800

**Number of visitors**
6.2 IT and project management at the EMEA

**IT Sector**

Major refurbishments and upgrades to the IT infrastructure were carried out at the EMEA in 2003. A new data storage system and a range of infrastructure facility enhancements were introduced for all delegates to improve the progress of meetings. These facilities include secure remote access to mail systems using Internet browser technology, video streaming and wireless LAN connections in meeting rooms.

The requirements and IT solution for business continuity and disaster recovery were defined and documented. The preparatory stages for the provision of new 8th floor computer room facilities were also completed. These facilities will provide high availability and back-up to the existing services currently made available from the 4th floor computer room. The dual computer room environment will provide appropriate levels of business continuity in the event of failures, which is essential for the EU telematics services being provided to both the EU regulatory authorities and industry. This major undertaking begun in 2003 will eventually lead to the creation of a second off-site IT infrastructure, mirroring mission-critical data and applications.

IT preparation for enlargement has had a major impact on the Sector workload in 2003, as telematics services must be made available to accession countries prior to 1 May 2004. Detailed planning and preparation with all new accession country institutions has taken place through the EudraNet telematics implementation group (TIG) in 2003, which the EMEA chairs.

**EMEA core applications**

The IT Sector maintained high levels of IT services throughout 2003, with more than 99.5% service availability. The EMEA help desk handled over 3,000 calls during the year.

The development of core applications continued, including the launch of the second module of the Meetings Management System (MMS) and continuation of the EMEA tracking systems development (SIAMED). Other applications that were further developed included the personnel database, SI2 and ActiTrak.

An area of key importance to the EMEA in 2003 was the implementation of secure communication systems. Several projects were undertaken during the year and remote access facilities were provided to a selected range of internal EMEA and EU Regulatory Authorities users. The Sector also provided support throughout 2003 to the EudraVigilance application. All European initiatives and activities were in line with the EU Telematics strategy (see chapter 5).

The IT Sector took over the coordination and management of EudraNet and was heavily involved in a range of Eudra IT projects in the pharmaceutical sector. The IT Sector provided full helpdesk facilities for EudraNet and maintained high levels of service availability, handling over 2,400 calls during the year.

In January 2003, the EudraLink application was launched to replace EudraSafe. This application was very successful and allows secure encrypted message delivery between EMEA, Member State Agencies and Industry. The application is based on "open source" products and has had a very large uptake, with over 1,600 users from EMEA, Member State Agencies and Industry using the service in November 2003. The IT Sector also provided full helpdesk, training and account management facilities for EudraLink and maintained high levels of service availability, handling over 2,400 calls during the year.

**Project management sector**

The project management sector approached its planned staffing levels towards the end of the year. Its workload comprised EU telematics projects (further described in chapter 5), the logistical support for the Pan-European Forum on Pharmaceuticals (PERF), and involvement in the implementation of the electronic document management system in the Agency.

The progress of the project to implement an electronic document management system was evaluated during the year. The business case was examined and enforced, the requirements were assessed with the users, and the focus of the implementation re-oriented. A new roll-out plan has been drawn up for the Agency.
6.3 Meeting management and conferences

Meeting activities increased compared to 2002, as the number of meetings organised by the EMEA excluding PERF meetings increased by 22 % (from 317 to 386). The number of meeting days also increased by 12 % (from 510 to 569). Interpretation days were reduced by 4 % (239 days in 2003 compared to 251 days in 2002), as interpretation was tailored to meet needs. A service level agreement was signed by the EMEA with the European Commission Joint Interpretation and Conference Service in order to better define interpretation requirements.

The workload of the sector increased by a further 20 % due to the following factors: increased number of delegates using the EMEA travel and hotel services; increased requirement for assistance to delegates; participation by representatives of New Member States in meetings as observers.

To meet the 20 % increase in travel bookings (over 3,000 bookings) expected in 2003, as well as reducing the travel management cost, a travel agency implant was set up at the EMEA premises in mid-2003, in order to streamline the booking process and the billing requirements, especially in preparation for the enlargement.

A total of 4,047 delegate visits were reimbursed, leading to an 11 % increase of expenditure compared to 2002.

A task force was set up to coordinate the participation of New Member States representatives in meetings as observers since 17 April 2003 and to assess the impact of the enlargement of the European Union in order to ensure that the resulting technical and logistical requirements are taken into account.

Refurbishment of delegate offices began in 2003 to accommodate representatives from the 10 new Member States after enlargement on 1 May 2004. The plans were drawn up after consultation with delegates.

The Sector played a role in facilitating relations with the Agency’s partners through the provision of videoconferencing facilities, teleconferencing and a new pilot project to broadcast meetings of scientific committees to national authorities to allow better input from experts. A video streaming/video conferencing feasibility report was prepared and activities were developed according to plan.
6.4 Document management and publishing

Document management

Documentum, the electronic document management system selected for implementation at the Agency, was subject to an external audit during the first half of 2003. As a result a number of activities, such as the review of user specification requirements were carried out in order to clarify and improve the project as a whole. The management of the project was transferred to a full-time project manager recruited in the Project management Sector.

Quality and coherence of regulatory documents

In the context of the enlargement of the European Union, the implications of the automatic extension of European Commission decisions granting marketing authorisations for medicinal products to the 10 new Member States on the date of accession were examined. A major consequence is the volume of translation work implicit in the requirement that product information be available in all the official languages of the European Union. In order to address this burden, it was agreed that such translations would be provided during the next regulatory transaction (e.g. variation or notification procedure) under a process known as the ‘common procedure’. Availability of these translated annexes will be an essential requirement to proceed with ongoing regulatory activities for existing centrally approved products and new applications after the accession date.

It was further proposed that pre-accession checks also be carried out in order to avoid peaks of activity both for regulators and industry, thereby enabling a more phased approach. In this way, delays in the supply of affected medicinal products in new Member States after EU enlargement will be avoided, and the circulation of such products with sub-standard product information translations will be prevented, thereby addressing potential public health concerns.

The EMEA therefore set up a ‘pre-accession linguistic review process’ to coordinate the review of the translations of the product information of the 195 human and 42 veterinary centrally authorised products in the 9 new EU languages. In order to be able to finance this specific exercise, and in particular, in order to support the work of the new Member States, the EMEA has put in place an administrative fee for this work.
Annexes

1. Members of the Management Board
2. Members of the Committee for Proprietary Medicinal Products
3. Members of the Committee for Veterinary Medicinal Products
4. Members of the Committee for Orphan Medicinal Products
5. National competent authority partners
6. EMEA budgets 2001 to 2003
7. CPMP opinions in 2003 on medicinal products for human use
8. CVMP opinions in 2003 on medicinal products for veterinary use
9. COMP opinions in 2003 on designation of orphan medicinal products
10. EMEA guidelines in 2003
11. Arbitration and Community referrals overview 2003
12. EMEA contact points and reference documents
Annex 1

Members of the Management Board

Chairman: Philippe DUNETON
EMEA contact: Martin HARVEY ALLCHURCH

Members

European Parliament
- Gianmartino BENZI, José-Luis VALVERDE LÓPEZ
  Alternates: Dietrich HENSCHLER, Jean-Pierre REYNIER

European Commission
- Jean-Paul MINGASSON, Fernand SAUER
  Alternates: Paul WEISSENBRE, Patricia BRUNO

Belgium
- Johan van CALSTER, Lionel LAURIER

Denmark
- IB VALSBORG, Jytte LYNGVIG (vice-chairman)

Germany
- Walter SCHWERDTFEGER, Ilse-Dore SCHÜTT

Greece
- Charalambos SAVAKIS, Thrasyvoulos KEFALAS

Spain
- Fernando GARCIA ALONSO, Carlos LENS CABRERA

France
- Martin HIRSCH

Ireland
- Tom MOONEY, Paddy ROGAN

Italy
- Nello MARTINI, Gaetana FERRI

Luxembourg
- Mariette BACKES-LIES, Claude A HEMMER

Netherlands
- Huib VAN DE DONK, Frits PLUIMERS

Austria
- Christian KALCHER, Robert SCHLÖGEL

Portugal
- Rui dos SANTOS IVO, Manuel NEVES DIAS

Finland
- Pekka JÄRVINEN, Hannes WAHLROOS

Sweden
- Birgitta BRATTHALL, Anders BROSTRÖM

United Kingdom
- Roy ALDER, Steve DEAN

Observers

Iceland
- Rannveig GUNNARSDÓTTIR, Ingolf J PETERSEN

Liechtenstein
- Brigitte BATLINER, Peter MALIN

Norway
- Kai FINNISIN, Gro Ramsten WESENBERG

1 Replaced Keith Jones as of December 2003 meeting.
2 Replaced André PAUWELS as of June 2003 meeting.
3 Replaced Frans GOSSELIN as of June 2003 meeting.
4 Elected at December 2003 meeting replacing Philippe Duneton as vice-chairman.
5 Replaced Hans-Peter HOFMANN as of October 2003 meeting.
6 Replaced Gerhard Josef KOTHMANN as of February 2003 meeting.
7 Replaced Michalis MARAGOUZAKIS as of June 2003 meeting.
8 Replaced Elias MOSSIALOS as of December 2003 meeting.
9 Resigned as of June 2003 meeting; no replacement nominated.
10 Resigned as of December 2003 meeting; no replacement nominated.
Annex 2

Members of the Committee for Proprietary Medicinal Products

Chair: Daniel BRASSEUR
EMEA contact: Anthony HUMPHREYS

Members

- Eric ABADIE (France) (vice-chairman)
- Mark AINSWORTH (Denmark)
- George AISLATNER (Greece)
- Fernando de ANDRES-TRELLES (Spain)
- Michalis AVGERINOS (Greece)
- Gonzalo CALVO ROJAS (Spain)
- Jens ERSBØLL (Denmark)
- Bruno FLAMION (Belgium)
- Silvio GARATTINI (Italy)
- Jacqueline GENOUX-HAMES (Luxembourg)
- Lars GRAMSTAD (Norway)
- Manfred HAASE (Germany)
- Ian HUDSON\(^1\) (United Kingdom)
- Magnús JÓHANNSSON (Iceland)
- Pekka KURKI (Finland)
- Frits LEKKERKERKER (Netherlands)
- David LYONS (Ireland)
- Pieter NEELS (Belgium)
- Per NILSSON (Sweden)
- Tilmann OTT\(^1\) (Germany)
- Heribert PITTNER (Austria)
- Jean-Louis ROBERT (Luxembourg)
- Pasqualino ROSSI (Italy)
- Frances ROTBLAT\(^2\) (United Kingdom)
- Patrick SALMON (Ireland)
- Tomas SALMONSON (Sweden)
- Cristina Sampaio (Portugal)
- Beatriz SILVA LIMA (Portugal)
- Eva SKOVLUND (Norway)
- Josef SUKO (Austria)
- Sigurdur THORSTEINSSON (Iceland)
- Markku TOIVONEN (Finland)
- Jean-Hugues TROUVIN (France)
- Barbara VAN ZWIETEN-BOOT (Netherlands)

1 Replaced Rolf BASS as of September 2003 meeting.
2 Replaced Peter ARLETT as of September 2003 meeting.
3 Replaced Alex NICHOLSON as of November 2003 meeting.
## Working parties and ad hoc groups

<table>
<thead>
<tr>
<th>Working party</th>
<th>Chair</th>
<th>EMEA contact</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biotechnology working party (CPMP BWP)</td>
<td>Jean-Hugues TROUVIN</td>
<td>John PURVES</td>
</tr>
<tr>
<td>Blood products working group (CPMP BPWP)</td>
<td>Manfred HAASE</td>
<td>John PURVES</td>
</tr>
<tr>
<td>Efficacy working party (CPMP EWP)</td>
<td>Barbara VAN ZWETEN-BOOT</td>
<td>Isabelle MOULON</td>
</tr>
<tr>
<td>Herbal medicinal products working party (CPMP HMPWP)</td>
<td>Konstantin KELLER</td>
<td>Isabelle MOULON</td>
</tr>
<tr>
<td>Pharmacovigilance working party (CPMP PhVWP)</td>
<td>Anne CASTOT (acting)</td>
<td>Panos TSINTIS</td>
</tr>
<tr>
<td>Safety working party (CPMP SWP)</td>
<td>Beatriz SILVA LIMA</td>
<td>Isabelle MOULON</td>
</tr>
<tr>
<td>Joint CPMP/CVMP quality working party (CPMP/CVMP QWP)</td>
<td>Jean-Louis ROBERT</td>
<td>Isabelle MOULON</td>
</tr>
<tr>
<td>Scientific advice working group (CPMP SAWG)</td>
<td>Markku TOIVONEN</td>
<td>Isabelle MOULON</td>
</tr>
<tr>
<td>Ad hoc expert group on cell therapy</td>
<td>Pekka KURKI</td>
<td>John PURVES</td>
</tr>
<tr>
<td>Ad hoc groups on chemical threats</td>
<td>Thomas SALMONSON</td>
<td>Isabelle MOULON</td>
</tr>
<tr>
<td>Ad hoc working group on (pre) clinical comparability of biotechnology products</td>
<td>Pekka KURKI</td>
<td>Isabelle MOULON</td>
</tr>
<tr>
<td>Ad hoc expert group on gene therapy (CPMP GTEG)</td>
<td>Klaus CICHUTEK</td>
<td>Marisa PAPALUCA AMATI</td>
</tr>
<tr>
<td>Paediatric expert group (CPMP PEG)</td>
<td>Daniel BRASSEUR</td>
<td>Agnès SAINT RAYMOND</td>
</tr>
<tr>
<td>Ad hoc expert group on pharmacogenetics</td>
<td>Eric ABADIE</td>
<td>Marisa PAPALUCA AMATI</td>
</tr>
<tr>
<td>Vaccine expert group (CPMP VEG)</td>
<td>Roland DOBBELAER</td>
<td>John PURVES</td>
</tr>
<tr>
<td>Therapeutic advisory group on anti-infectives</td>
<td>Bjanne ORSKOV LINDHARDT</td>
<td>Isabelle MOULON</td>
</tr>
<tr>
<td>Therapeutic advisory group on diagnostics</td>
<td>To be appointed</td>
<td>Panos TSINTIS</td>
</tr>
<tr>
<td>Therapeutic advisory group on oncology</td>
<td>Michel MARTY</td>
<td>Isabelle MOULON</td>
</tr>
<tr>
<td>Working group with patients organisations</td>
<td>Frits LEKKERKERKER/Noël WATHION</td>
<td>Isabelle MOULON</td>
</tr>
</tbody>
</table>
Annex 3
Members of the Committee for Veterinary Medicinal Products

Chair: Gérard MOULIN
EMEA contact: Peter JONES

Members

- Margarita ARBOIX (Spain)
- J. Gabriel BEECHINOR (Ireland)
- Hanne BERGENDAHL (Norway)
- Marie-Anne BOTREL (France)
- Rory BREATHNACH (Ireland)
- Ivo CLAASSEN* (Netherlands)
- Ricardo de la FUENTE (Spain)
- Johannes DICHTL (Austria)
- Virgilio DONINI (Italy)
- Françoise FALIZE (Belgium)
- Christian FRIIIS (Denmark)
- Helle HARTMANN FRIES (Denmark)
- Johannes HOOGLAND (Netherlands), (vice-chairman)
- Tonje HØY (Norway)
- Martin ILOTT* (United Kingdom)
- Eva FABIANSON-JOHNSSON (Sweden)
- Liisa KAARTINEN (Finland)
- Reinhard KROKER (Germany)
- Jan LUTHMAN (Sweden)
- Agostino MACRI (Italy)
- Ioannis MALEMIS (Greece)
- Eduardo MARQUES FONTES (Portugal)
- Maria Leonor MEISEL (Portugal)
- Manfred MOOS (Germany)
- John O’BRIEN (United Kingdom)
- Eugen OBERMAYR (Austria)
- Sigurdur ÖRN HANSSON (Iceland)
- Orestis PAPADOPOULOS (Greece)
- Halldór RUNÓLFSSON (Iceland)
- Jean-Claude ROUBY (France)
- Liisa SIHVONEN (Finland)
- Bruno URBAIN (Belgium)
- Marc WIRTOR (Luxembourg)

1 Replaced Herman LENSING as of April 2003 meeting
2 Replaced David MACKAY as of December 2003 meeting
## Working parties and ad hoc groups

<table>
<thead>
<tr>
<th>Working Party</th>
<th>Chair</th>
<th>EMEA Contact</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Efficacy working party (CVMP EWP)</strong></td>
<td>Liisa KAARTINEN</td>
<td>Jill ASHLEY-SMITH</td>
</tr>
<tr>
<td><strong>Safety working party (CVMP SWP)</strong></td>
<td>Christian FRIIS</td>
<td>Kornelia GREIN</td>
</tr>
<tr>
<td><strong>Immunologicals working party (CVMP IWP)</strong></td>
<td>Orestis PAPADOPOULOS¹</td>
<td>Jill ASHLEY-SMITH</td>
</tr>
<tr>
<td><strong>Ad hoc group on antimicrobial resistance (CVMP AGAR)</strong></td>
<td>Margarita ARBOIX</td>
<td>Kornelia GREIN</td>
</tr>
<tr>
<td><strong>Pharmacovigilance working party (CVMP PhVWP)</strong></td>
<td>Cornelia IBRAHIM</td>
<td>Kornelia GREIN</td>
</tr>
<tr>
<td><strong>Ad hoc group on environmental risk assessment (CVMP AHGERA)</strong></td>
<td>Hans HOOGLAND</td>
<td>Kornelia GREIN</td>
</tr>
<tr>
<td><strong>Joint CPMP/CVMP quality working party</strong></td>
<td>Jean-Louis ROBERT</td>
<td>Emer COOKE</td>
</tr>
</tbody>
</table>

¹ Replaced David MACKAY as of December 2003 meeting.
Annex 4

Members of the Committee for Orphan Medicinal Products

Chair: Josep TORRENT i FARNELL
EMEA contact: Agnès SAINT RAYMOND

Members

- Eric ABADIE (EMEA representative)
- Gianmartino BENZI (EMEA representative)
- Heidrun BOSCH-TRABERG (Denmark)
- Birthe BYSKOV HOLM* (patient organisation representative)
- Rembert ELBERS (Germany)
- José Manuel GIÃO TOSCANO RICO (Portugal)
- Lars GRAMSTAD (Norway)
- Emmanuel HERON (France)
- Kalle HOPPU (Finland)
- Bernd JILMA (Austria)
- Alastair KENT (patient organisation representative)
- Yann LE CAM (patient organisation representative), (vice-chairman)
- André LHOIR (Belgium)
- David LYONS (EMEA representative)
- José Félix OLALLA MARAÑÓN (Spain)
- Henri METZ (Luxembourg)
- Harrie SEEVERENS (The Netherlands)
- Rashmi SHAH (United Kingdom)
- George SHORTEN (Ireland)
- George STATHOPOULOS (Greece)
- Domenica TARUSCIO (Italy)
- Sigurdur THORSTEINSSON (Iceland)
- Kerstin WESTERMARK (Sweden)

Working parties and ad hoc groups

Ad-Hoc biotechnology working group (COMP BWG)
Chair: Harrie SEEVERENS/Jean-Hugues TROUVIN
EMEA contact: Agnès SAINT RAYMOND

Prevalence ad-hoc working group
Chair: Kalle HOPPU
EMEA contact: Agnès SAINT RAYMOND

Working group with interested parties (COMP WGIP)
Chair: Yann LE CAM/Agnès SAINT RAYMOND
EMEA contact: Agnès SAINT RAYMOND

* Replaced Moisés ABASCAL ALONSO as of May 2003 meeting.
2 Replaced Randi NORDAL as of May 2003 meeting.
3 Replaced Brendan BUCKLEY as of November 2003 meeting.
4 Replaced François MEYER as of May 2003 meeting.
Annex 5
National competent authority partners

Further information on the national competent authorities is also available on the national authorities’ Internet sites:

BELGIUM

Johan van CALSTER
Generaal Adviseur
Federale Overheidsdienst Volksgezondheid,
Veiligheid van de Voedselketen
Directoraat-Generaal Bescherming Volksgezondheid
en Leefmilieu
Geneesmiddelen – DGG
33 Bischoffsheimlaan
Building Amazone
B – 1000 Brussel
Tel: (32-2) 210 94 46
Fax: (32-2) 227 55 54
E-mail: johan.vancalster@health.fgov.be
Internet: http://www.afigp.fgov.be

DENMARK

Jytte LYNGVIG
Direktør
Lægemiddelstyrelsen
Axel Heides Gade 1
DK – 2300 København S
Tel: (45) 44 88 93 34
Fax: (45) 44 88 95 59
E-mail: jyl@dkma.dk
Internet: http://www.laegemiddelstyrelsen.dk

GERMANY

Harald SCHWEIM
Direktor
Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM)
Kurt-Georg-Kiesinger-Allee 3
D - 53175 Bonn
Tel: (49-228) 207 32 03
Fax: (49-228) 207 55 14
E-mail: schweim@bfarm.de
Internet: http://www.bfarm.de

Reinhard KROKER
Leiter des Fachbereichs
BVL- Bundesamt für Verbraucherschutz und
Lebensmittelsicherheit
Diedersdorfer Weg 1
D – 12277 Berlin
Tel: (49-1888) 412 23 64
Fax: (49-1888) 412 29 65
E-mail: r.kroker@bvl.bund.de
Internet: http://www.bvl.bund.de

Johannes LÖWER
Präsident
Bundesamt für Sera und Impfstoffe
Paul-Ehrlich-Institut
Paul-Ehrlich Straße 51-59
D – 63225 Langen
Tel: (49-6103) 77 10 00
Fax: (49-6103) 77 12 40
E-mail: loejo@pei.de
Internet: http://www.pei.de
GREECE
Charlambos SAVAKIS
President
National Organization for Medicines
284 Mesogeion Av.
Holargos
GR – 155 62 Athens
Tel: (30-210) 650 72 10
Fax: (30-210) 654 95 86
E-mail: president@eof.gr

SPAIN
Carlos LENS CABRERA
Director
Agencia Española de Medicamentos y Productos Sanitarios
Calle Alcalá 56
E - 28071 Madrid
Tel: (34-91) 822 50 44
Fax: (34-91) 822 50 10
E-mail: sdaem@agemed.es
Internet: http://www.agemed.es

LIECHTENSTEIN
Brigitte BATLINER
Kontrollstelle für Arzneimittel, beim Amt für Lebensmittelkontrolle und Veterinärwesen
Postplatz 2
Postfach 37
FL – 9494 Schaan
Tel: (423) 236 73 25
Fax: (423) 236 73 10
E-mail: brigitte.batliner@alkvw.llv.li

FRANCE
Jean MARIMBERT
Directeur Général
Agence Française de Sécurité Sanitaire des Produits de Santé
143-147, boulevard Anatole France
F – 93285 Saint-Denis CEDEX
Tel: (33-1) 55 87 30 14
Fax: (33-1) 55 87 30 12
E-mail: jean.marimbert@afssaps.sante.fr
Internet: http://www.afssaps.sante.fr

Patrick DEHAUMONT
Directeur ANMV
Agence Française de Sécurité Sanitaire des Aliments
Laboratorie des Médicaments Vétérinaires
BP 90 203 Javené
F – 35302 Fougères Cedex
Tel: (33-2) 99 94 78 71
Fax: (33-2) 99 94 78 99
E-mail: p.dehaumont@anmv.afssa.fr
Internet: http://www.afssa.fr

IRELAND
Pat O’MAHONY
Irish Medicines Board – Bord Leigheasra na hÉirann
Earlsfort Centre
Earlsfort Terrace
IRL – Dublin 2
Tel: (353-1) 676 49 71
Fax: (353 1) 661 47 64
E-mail: pat.omahony@imb.ie
Internet: http://www.imb.ie

ICELAND
Rannveig GUNNARSDÓTTIR
Director
Lyfjastofnun
Eidistorg 13-15
PO Box 180
IS – 172 Seltjarnarnes
Tel: (354) 520 21 00
Fax: (354) 561 21 70
E-mail: rannveig.gunnarsdottir@lyfjastofnun.is
Internet: http://www.lyfjastofnun.is
ITALY

Nello MARTINI
Direttore Generale del Dipartimento Valutazione Medicinali e Farmacovigilanza Ministero della Salute
Viale della Ciuità Romana, 7
I – 00144 Roma
Tel: (39-06) 59 94 36 66
Fax: (39-06) 59 94 34 65
E-mail: n.martini@sanita.it
Internet: http://www.sanita.it/farmaci

Romano MARABELLI
Direttore Generale
Ministero della Salute
Servizi Veterinari Roma
Piazzale Marconi 25
I – 00144 Roma
Tel: (39-06) 59 94 49 45
Fax: (39-06) 59 94 32 17
E-mail: alimentivet@sanita.it

NETHERLANDS

Aginus A. W KALIS
Executive Director
College Ter Beoordeling van Geneesmiddelen Agentschap
Kalvermarkt 53
Postbus 16229
2500 CB Den Haag
Nederland
Tel: (31-70) 356 74 00
Fax: (31-70) 356 75 15
E-mail: aaw.kalis@cbg-meb.nl
Internet: http://www.cbg-meb.nl

W.L.M. KAPITEIN
Head
Bureau Registratie Diergeneesmiddelen
Postbus 289
6700 AG Wageningen
Nederland
Tel: (31-317) 46 57 31
Fax: (31-317) 42 31 93
E-mail: w.l.m.kapitein@minlnv.nl

LUXEMBOURG

Mariette BACKES-LIES
Pharmacien-Inspecteur – Chef de Division Direction de la Santé Division de la Pharmacie et des Médicaments Villa Louvigny – 1er étage Parc de la Ville – Allée Marconi L – 2120 Luxembourg Tel: (352) 478 55 90 Fax: (352) 26 20 01 40/47 E-mail: dpmlux@pt.lu

NORWAY

Gro Ramsten WESENBERG
Director General Statens legemiddelverk
Sven Oftedals vei 8
N – 0950 Oslo
Tel: (47-22) 89 77 01
Fax: (47-22) 89 77 99
E-mail: gro.wesenberg@legemiddelverket.no
Internet: http://www.legemiddelverket.no
http://www.NoMA.no
AUSTRIA

Hubert HRABCIK
Bundesministerium für Gesundheit und Frauen
Radetzkystraße 2
A – 1030 Wien
Tel: (43-1) 711 00 47 17
Fax: (43-1) 711 00 48 30
E-mail: hubert.hrabcik@bmgf.gv.at

PORTUGAL

Rui SANTOS IVO
Presidente
Conselho de Administração
Instituto Nacional da Farmácia e do Medicamento
(INFARMED)
Parque de Saúde de Lisboa
Av. do Brasil, 53
P – 1749-004 Lisboa
Tel: (351-21) 798 71 09
Fax: (351-21) 798 71 20
E-mail: rsantos.ivo@infarmed.pt
Internet: http://www.infarmed.pt

FINLAND

Hannes WAHLROOS
Ylijohtaja
Lääkelaitos - Läkemedelsverket
Mannerheimintie 166
PL 55
FIN – 00300 Helsinki
Tel: (358-9) 47 33 42 00
Fax: (358-9) 47 33 43 45
E-mail: hannes.wahlroos@nam.fi
Internet: http://www.nam.fi

SWEDEN

Gunnar ALVÁN
Generaldirektör
Läkemedelsverket
Dag Hammarskjöld’s väg 42
S - 751 83 Uppsala
Tel: (46-18) 17 46 00
Fax: (46-18) 54 85 66
E-mail: gunnar.alvan@mpa.se
Internet: http://www.mpa.se

UNITED KINGDOM

Kent WOODS
Chief Executive
Medicines and Healthcare products Regulatory Agency
Market Towers
1 Nine Elms Lane
London SW8 5NQ
United Kingdom
Tel: (44-20) 70 84 25 46
Fax: (44-20) 70 84 25 48
E-mail: kent.woods@mhra.gsi.gov.uk
Internet: http://www.mhra.gov.uk/

Steve DEAN
Chief Executive
Veterinary Medicines Directorate
Woodham Lane
New Haw, Addlestone
Surrey KT15 3LS
United Kingdom
Tel: (44-1932) 33 83 01
Fax: (44-1932) 33 66 18
E-mail: s.dean@vmd.defra.gsi.gov.uk
Internet: http://www.vmd.gov.uk/
Annex 6
EMEA budget summaries 2002 – 2004

The summarised comparative budget statements for 2002 to 2004 are as follows: (Amounts expressed in euro)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fees</td>
<td>39 000 000 63.61 %</td>
<td>56 742 000 67.41 %</td>
<td>64 800 000 67.08 %</td>
</tr>
<tr>
<td>General EU contribution</td>
<td>17 135 000 27.95 %</td>
<td>12 300 000 14.61 %</td>
<td>17 500 000 18.11 %</td>
</tr>
<tr>
<td>Special EU contribution for IT telematics strategy</td>
<td>-</td>
<td>7 000 000 8.32 %</td>
<td>7 500 000 7.76 %</td>
</tr>
<tr>
<td>Special EU contribution for orphan medicinal products</td>
<td>2 750 000 4.49 %</td>
<td>3 100 000 3.68 %</td>
<td>3 500 000 3.62 %</td>
</tr>
<tr>
<td>Contribution from EEA</td>
<td>366 000 0.60 %</td>
<td>558 000 0.66 %</td>
<td>573 000 0.59 %</td>
</tr>
<tr>
<td>Contribution from EU programmes (PERF)</td>
<td>213 000 0.35 %</td>
<td>1 530 000 1.82 %</td>
<td>p.m. 0.00 %</td>
</tr>
<tr>
<td>Other</td>
<td>1 840 000 3.00 %</td>
<td>2 949 000 3.50 %</td>
<td>2 746 000 2.84 %</td>
</tr>
<tr>
<td><strong>TOTAL REVENUE</strong></td>
<td>61 304 000 100.00 %</td>
<td>84 179 000 100.00 %</td>
<td>96 619 000 100.00 %</td>
</tr>
</tbody>
</table>

| **Expenditure**       |                     |                     |                     |
| **Staff**             |                     |                     |                     |
| Salaries              | 24 337 000 39.70 %  | 27 352 500 32.49 %  | 32 596 000 33.74 %  |
| Interim and other support persons | 1 760 000 2.87 % | 1 845 000 2.19 % | 2 046 000 2.12 % |
| Other staff-related expenditure | 1 502 000 2.45 % | 2 355 500 2.80 % | 2 493 000 2.58 % |
| **Total title 1**     | 27 599 000 45.02 %  | 31 553 000 37.48 %  | 37 135 000 38.44 %  |

| **Building/equipment** |                     |                     |                     |
| Rent/charges           | 5 526 000 9.01 %    | 5 686 000 6.76 %    | 5 670 000 5.87 %    |
| Expenditure on data processing | 3 083 000 5.03 % | 9 517 000 11.31 % | 8 209 000 8.50 % |
| Other capital expenditure | 491 000 0.80 % | 1 959 000 2.33 % | 1 737 000 1.80 % |
| Postage and communications | 264 000 0.43 % | 418 000 0.50 % | 505 000 0.52 % |
| Other administrative expenditure | 2 043 000 3.33 % | 2 075 000 2.46 % | 2 780 000 2.88 % |
| **Total title 2**      | 11 407 000 18.60 %  | 19 655 000 23.35 %  | 18 901 000 19.56 %  |

| **Operational expenditure** |                     |                     |                     |
| Meetings                  | 3 535 000 5.77 %    | 3 946 800 4.70 %    | 8 835 000 9.14 %    |
| Evaluations               | 17 855 500 29.14 %  | 26 810 800 31.85 %  | 30 075 000 31.13 %  |
| Translation               | 477 000 0.78 %      | 701 000 0.83 %      | 1 375 000 1.42 %    |
| Studies and consultants   | 98 500 0.16 %       | 27 000 0.03 %       | 50 000 0.05 %       |
| Publications              | 119 000 0.19 %      | 78 000 0.09 %       | 248 000 0.26 %      |
| EU programmes             | 213 000 0.34 %      | 1 407 400 1.67 %    | p.m. 0.00 %         |
| **Total title 3**         | 22 298 000 36.38 %  | 32 971 000 39.17 %  | 40 583 000 42.00 %  |
| **TOTAL EXPENDITURE**     | 61 304 000 100.00 % | 84 179 000 100.00 % | 96 619 000 100.00 % |

**Notes**
# Annex 7

**CPMP opinions in 2003 on medicinal products for human use**

## Positive CPMP opinions

<table>
<thead>
<tr>
<th>Product</th>
<th>Marketing authorisation holder</th>
<th>Therapeutic area</th>
<th>EMEA/CPMP</th>
<th>European Commission</th>
</tr>
</thead>
</table>
| • Aldurazyme#  
  • laronidase  
  • Part A | Genzyme BV | • A16AB05  
  • Enzyme replacement therapy in patients with Mucopolysaccharidosis I (MPS I; α-L-iduronidase deficiency) | • 26.3.2002  
  • 20.2.2003  
  • 205 days  
  • 119 days | • 8.4.2003  
  • 10.6.2003  
  • 12.6.2003  
  • OJ C 153, 1.7.2003, p. 2 |
| • Fuzeon  
  • enfuvirtide  
  • Part B | Roche Registration Ltd | • J05A X (pending)  
  • Treatment of HIV-1 infection in combination with other antiretroviral agents. | • 21.10.2002  
  • 19.3.2003  
  • 9 days | • 15.4.2003  
  • 27.5.2003  
  • 29.5.2003  
  • OJ C 153, 1.7.2003, p. 2 |
| • Busilvex#  
  • busulfan  
  • Part B | Pierre Fabre Medicament | • L01AB01  
  • Treatment prior to conventional haematopoietic progenitor cell transplantation (HPCT) | • 26.3.2002  
  • 19.3.2003  
  • 173 days  
  • 180 days | • 7.5.2003  
  • 8.7.2003  
  • 11.7.2003  
  • OJ C 176, 25.7.2003, p. 2 |
| • Humira  
  • adalimumab  
  • Part A | Abbott Laboratories | • L04AA  
  • Treatment of moderate to severe, active rheumatoid arthritis in adult after inadequate response to disease-modifying anti-rheumatic drugs including methotrexate | • 22.4.2002  
  • 22.5.2003  
  • 181 days  
  • 209 days | • 10.7.2003  
  • 1.9.2003  
  • 3.9.2003  
  • OJ C 230, 26.9.2003, p. 5 |
| • Trudexa  
  • adalimumab  
  • Part A | Abbott Laboratories | • L04AA  
  • Treatment of moderate to severe, active rheumatoid arthritis in adult after inadequate response to disease-modifying anti-rheumatic drugs including methotrexate | • 22.4.2002  
  • 22.5.2003  
  • 181 days  
  • 209 days | • 10.7.2003  
  • 1.9.2003  
  • 3.9.2003  
  • OJ C 230, 26.9.2003, p. 5 |
| • Ventavis#  
  • iloprost  
  • Part B | Schering AG | • B01AC  
  • Treatment of patients with primary pulmonary hypertension, classified as NYHA functional class III | • 28.1.2002  
  • 22.5.2003  
  • 209 days  
  • 265 days | • 9.7.2003  
  • 16.9.2003  
  • 18.9.2003  
  • OJ C 262, 31.10.2003, p. 2 |
| • Onsenal#  
  • celecoxib  
  • Part B | Pharmacia-Pfizer EEIG | • L01XX  
  • Indicated for the reduction of adenomatous intestinal polyps in familial adenomatous polyposis (FAP), as an adjunct to surgery | • 20.11.2001  
  • 26.6.2003  
  • 208 days  
  • 369 days | • 12.8.2003  
  • 17.10.2003  
  • 22.10.2003  
  • OJ C 285, 28.11.2003, p. 5 |
| • Omnitrop  
  • somatropin  
  • Part A | Sandoz GmbH | • H01AC01  
  • Treatment of growth hormone deficiency | • 22.5.2001  
  • 26.6.2003  
  • 210 days  
  • 544 days |  |

# Denotes an orphan medicinal product designated under Regulation (EC) No 121/2000
<table>
<thead>
<tr>
<th>Product</th>
<th>Marketing authorisation holder</th>
<th>Therapeutic area</th>
<th>EMEA/CPMP</th>
<th>European Commission</th>
</tr>
</thead>
<tbody>
<tr>
<td>• <strong>Avandamet</strong></td>
<td>SmithKline Beecham plc</td>
<td>• A10BH01 - Treatment of type 2 diabetes mellitus, particularly overweight patients unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone</td>
<td>21.10.2002</td>
<td>14.08.2003</td>
</tr>
<tr>
<td>• Part B</td>
<td></td>
<td></td>
<td>178 days</td>
<td>22.10.2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>67 days</td>
<td>OJ C 285, 28.11.2003, p. 5</td>
</tr>
<tr>
<td>• <strong>Stalevo</strong></td>
<td>Orion Corporation</td>
<td>• N04BA03 - Treatment of patients with Parkinson’s disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (DDC) inhibitor treatment</td>
<td>23.9.2002</td>
<td>12.8.2003</td>
</tr>
<tr>
<td>• levodopa, carbidopa, entacapone</td>
<td></td>
<td></td>
<td>26.6.2003</td>
<td>17.10.2003</td>
</tr>
<tr>
<td>• Part B</td>
<td></td>
<td></td>
<td>194 days</td>
<td>22.10.2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>79 days</td>
<td>OJ C 285, 28.11.2003, p. 5</td>
</tr>
<tr>
<td>• <strong>Dukoral</strong></td>
<td>SBL Vaccin AB</td>
<td>• J07AE01 - Immunisation against Vibrio cholerae serogroup O1 in adults and children from 2 years of age visiting endemic epidemic areas</td>
<td>23.3.2002</td>
<td>10.9.2003</td>
</tr>
<tr>
<td>• vibrio cholerae and recombinant cholera toxin B-submit</td>
<td></td>
<td></td>
<td>24.7.2003</td>
<td></td>
</tr>
<tr>
<td>• Part A</td>
<td></td>
<td></td>
<td>201 days</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>277 days</td>
<td></td>
</tr>
<tr>
<td>• <strong>Xagrid</strong></td>
<td>Shire Pharmaceutical Contracts Ltd</td>
<td>• L01X - Reduction of elevated platelet in at risk essential thrombocythaemia</td>
<td>22.4.2002</td>
<td>10.9.2003</td>
</tr>
<tr>
<td>• anagrelide</td>
<td></td>
<td></td>
<td>24.7.2003</td>
<td>24.10.2003</td>
</tr>
<tr>
<td>• Part B</td>
<td></td>
<td></td>
<td>181 days</td>
<td>28.10.2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>271 days</td>
<td>OJ C 285, 28.11.2003, p. 5</td>
</tr>
<tr>
<td>• <strong>Emtriva</strong></td>
<td>Triangle Pharma Ltd</td>
<td>• J05AF09 - Treatment of HIV-1 infection in combination with other antiretroviral agents</td>
<td>6.1.2003</td>
<td>10.9.2003</td>
</tr>
<tr>
<td>• emtricitabine</td>
<td></td>
<td></td>
<td>24.7.2003</td>
<td>24.10.2003</td>
</tr>
<tr>
<td>• Part B</td>
<td></td>
<td></td>
<td>170 days</td>
<td>28.10.2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>28 days</td>
<td>OJ C 285, 28.11.2003, p. 5</td>
</tr>
<tr>
<td>• <strong>Emend</strong></td>
<td>Merck Sharp &amp; Dohme</td>
<td>• A04A - Prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy</td>
<td>18.11.2002</td>
<td>10.9.2003</td>
</tr>
<tr>
<td>• aprepitant</td>
<td></td>
<td></td>
<td>24.7.2003</td>
<td>11.10.2003</td>
</tr>
<tr>
<td>• Part B</td>
<td></td>
<td></td>
<td>182 days</td>
<td>13.11.2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>64 days</td>
<td>OJ C 285, 28.11.2003, p. 5</td>
</tr>
<tr>
<td>• <strong>Zevalin</strong></td>
<td>Schering AG</td>
<td>• L01XC - Treatment of adult patients with rituximab relapsed or refractory CD20+ follicular B-cell non-Hodgkin’s lymphoma (NHL)</td>
<td>24.3.2003</td>
<td>12.11.2003</td>
</tr>
<tr>
<td>• ibritumomab tiuxetan</td>
<td></td>
<td></td>
<td>25.9.2003</td>
<td>16.1.2004</td>
</tr>
<tr>
<td>• Part A</td>
<td></td>
<td></td>
<td>153 days</td>
<td>21.1.2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>28 days</td>
<td>OJ C 52, 27.2.2004, p. 2</td>
</tr>
<tr>
<td>• <strong>Ibandronic acid Roche 2.5 mg film-coated tablet</strong></td>
<td>Roche Registration Ltd</td>
<td>• M05BA06 - Treatment of osteoporosis in postmenopausal women to reduce the risk of vertebral fractures</td>
<td>22.7.2002</td>
<td>16.12.2003</td>
</tr>
<tr>
<td>• Part B</td>
<td></td>
<td></td>
<td>207 days</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>244 days</td>
<td></td>
</tr>
<tr>
<td>• <strong>Bonviva</strong></td>
<td>Roche Registration Ltd</td>
<td>• M05BA06 - Treatment of osteoporosis in postmenopausal women in order to reduce the risk of vertebral fractures</td>
<td>22.7.2002</td>
<td>16.12.2003</td>
</tr>
<tr>
<td>• ibandronic acid</td>
<td></td>
<td></td>
<td>22.10.2003</td>
<td></td>
</tr>
<tr>
<td>• Part B</td>
<td></td>
<td></td>
<td>207 days</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>244 days</td>
<td></td>
</tr>
<tr>
<td>• <strong>Litak</strong></td>
<td>Lipomed GmbH</td>
<td>• L01BB04 - Symptomatic treatment of advanced adrenal cortical carcinoma</td>
<td>22.7.2002</td>
<td></td>
</tr>
<tr>
<td>• cladribine</td>
<td></td>
<td></td>
<td>22.10.2003</td>
<td></td>
</tr>
<tr>
<td>• Part B</td>
<td></td>
<td></td>
<td>206 days</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>244 days</td>
<td></td>
</tr>
</tbody>
</table>

# Denotes an orphan medicinal product designated under Regulation (EC) No 121/2000
<table>
<thead>
<tr>
<th>Product</th>
<th>Marketing authorisation holder</th>
<th>Therapeutic area</th>
<th>EMEA/CPMP</th>
<th>European Commission</th>
</tr>
</thead>
</table>
| Advate     | Baxter AG                      | • B02BD02  
• Treatment and prophylaxis of bleeding in haemophilia A (congenital factor VIII deficiency) | • 21.10.2002  
• 22.10.2003  
• 200 days  
• 156 days | • 8.1.2004 |
| octocog alfa |                                |                                          |           |                     |
| Part A     |                                |                                          |           |                     |
| Oxybutynin | Nicobrand Ltd                  | • L04BD04  
• Treatment of urge incontinence in unstable bladder | • 24.2.2003  
• 20.11.2003  
• 180 days  
• 87 days |                   |
| oxybutynin |                                |                                          |           |                     |
| Part B     |                                |                                          |           |                     |
| Faslodex   | AstraZeneca                    | • L02BA03  
• Treatment of locally advanced or metastatic breast cancer | • 24.2.2003  
• 20.11.2003  
• 176 days  
• 54 days | • 19.1.2004 |
| fulvestrant |                                |                                          |           |                     |
| Part B     |                                |                                          |           |                     |
| Cholestagel | Genzyme BV                    | • C10AC04  
• Adjunctive therapy to diet for the reduction of LDL cholesterol | • 23.9.2002  
• 20.11.2003  
• 201 days  
• 204 days | • 12.1.2004 |
| colesevelam hydrochloride |                        |                                          |           |                     |
| Part B     |                                |                                          |           |                     |
| Reyataz    | Bristol Myers Squibb Pharma EEIG | • J05AE  
• Combination treatment of HIV-1 infection | • 20.5.2002  
• 20.11.2003  
• 200 days  
• 326 days | • 12.1.2004 |
| atazanavir sulphate |                        |                                          |           |                     |
| Part B     |                                |                                          |           |                     |
| Photobarr# | Axcan International Pharma BV  | • L01CD01  
• Ablation of high-grade dysplasia (HGD) in patients with Barrett’s Esophagus (BE) | • 20.5.2002  
• 18.12.2003  
• 197 days  
• 321 days |                   |
| porfimer sodium |                                |                                          |           |                     |
| Part B     |                                |                                          |           |                     |

**Negative CPMP opinions**

<table>
<thead>
<tr>
<th>Product</th>
<th>Marketing authorisation holder</th>
<th>Therapeutic area</th>
<th>EMEA/CPMP</th>
<th>European Commission</th>
</tr>
</thead>
</table>
| Yondelis#  | PharmaMar S.A.                 | • pending  
• Treatment of patients with advanced soft tissue sarcoma after failure of conventional chemotherapy | • 20.11.2001  
• 24.7.2003  
• 207 days  
• 390 days | • 6.1.2004 |
| ecteinascidin |                                |                                          |           |                     |
| Part B     |                                |                                          |           |                     |
| Serostim#  | Ares Serono (Europe) Ltd       | • H01A  
• Treatment of AIDS wasting | • 17.7.2001  
• 25.4.2003  
• 177 Days  
• 460 Days | • 3.10.2003  
• 1.12.2003  
• 3.12.2003  
| somatropin |                                |                                          |           | OJ C 6, 10.1.2004, p. 2 |
| Part A     |                                |                                          |           |                     |

*Denotes an orphan medicinal product designated under Regulation (EC) No 121/2000*
## Positive CVMP opinions

<table>
<thead>
<tr>
<th>Product</th>
<th>Marketing authorisation holder</th>
<th>Therapeutic area</th>
<th>EMEA/CVMP</th>
<th>European Commission</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Metacam • meloxicam • Part B extension</td>
<td>Merial</td>
<td>• Pigs · Diarrhoea/respiratory infections/MMA</td>
<td>• 18.12.2001 · 15.1.2003 · 204 days · 148 days</td>
<td>• 27.2.2003 · 12.5.2003 · 14.5.2003 · OJ C 129, 3.6.2003, p. 18</td>
</tr>
<tr>
<td>• Metacam • meloxicam • Part B extension</td>
<td>Merial</td>
<td>• Cattle · Mastitis</td>
<td>• 10.3.2002 · 15.1.2003 · 150 days · 120 days</td>
<td>• 27.2.2003 · 12.5.2003 · 14.5.2003 · OJ C 129, 3.6.2003, p. 18</td>
</tr>
<tr>
<td>• Gonazon • azagly-nafarelin • Part B</td>
<td>Intervet International</td>
<td>• Female Salmonid fish · Ovulation induction and synchronization</td>
<td>• 18.12.2001 · 9.4.2003 · 204 days · 274 days</td>
<td>• 28.5.2003 · 22.7.2003 · 24.7.2003 · OJ C 204, 29.8.2003, p. 6</td>
</tr>
<tr>
<td>• Metacam • meloxicam • Part B extension</td>
<td>Merial</td>
<td>• Horses · Muscle – skeletal disorders</td>
<td>• 12.11.2002 · 18.6.2003 · 210 days · 8 days</td>
<td>• 1.8.2003 · 8.10.2003 · 10.10.2003 · OJ C 262, 31.10.2003, p. 6</td>
</tr>
<tr>
<td>• Draxxin • tulathroycin • Part B</td>
<td>Pfizer</td>
<td>• Cattle and pigs · Treatment of respiratory disease</td>
<td>• 15.10.2002 · 23.7.2003 · 182 days · 99 days</td>
<td>• 6.9.2003 · 11.11.2003 · 13.11.2003 · OJ C 285, 28.11.2003, p. 5</td>
</tr>
<tr>
<td>• Ibaflin • ibafloxacin • Part B extension</td>
<td>Intervet</td>
<td>• Dogs</td>
<td>• 13.8.2002 · 17.9.2003 · 210 days · 189 days</td>
<td>• 30.10.2003</td>
</tr>
<tr>
<td>• Gallivac HTV IBD • live vaccine • Part A extension</td>
<td>Merial</td>
<td>• Chickens</td>
<td>• 15.10.2002 · 15.10.2003 · 204 days · 162 days</td>
<td>• 1.12.2003</td>
</tr>
<tr>
<td>• Metacam 5mg/ml • meloxicam • Part B extension</td>
<td>Merial</td>
<td>• Cattle and pigs</td>
<td>• 14.10.2003 · 10.12.2003 · 57 days · 0 days</td>
<td>• 22.1.2004</td>
</tr>
<tr>
<td>• Novem 5mg/ml • meloxicam • Part B abridged</td>
<td>Merial</td>
<td>• Cattle · Muscle – skeletal disorders</td>
<td>• 15.10.2003 · 10.12.2003 · 57 days · 0 days</td>
<td>• 5.1.2004</td>
</tr>
<tr>
<td>• Novem 20mg/ml • meloxicam • Part B abridged</td>
<td>Merial</td>
<td>• Cattle · Muscle – skeletal disorders</td>
<td>• 15.10.2003 · 10.12.2003 · 57 days · 0 days</td>
<td>• 5.1.2004</td>
</tr>
</tbody>
</table>

There were no negative opinions in 2003.
### Establishment of maximum residue limits for new substances

<table>
<thead>
<tr>
<th>Substance INN</th>
<th>Therapeutic area</th>
<th>EMEA/CVMP</th>
<th>European Commission</th>
</tr>
</thead>
<tbody>
<tr>
<td>• cypermethrin (extension)</td>
<td>Salmonidae</td>
<td>• 29.7.1996, 15.1.2003, 335 days, 483 days</td>
<td>• 14.2.2003, 17.6.2003, OJ L 149, 17.6.2003, p. 15</td>
</tr>
<tr>
<td>• phoxim (extension)</td>
<td>Chicken</td>
<td>• 17.10.2002, 18.6.2003, 120 days, 124 days</td>
<td>• 17.7.2003, 15.11.2003, OJ L 297, 15.11.2003, p. 15</td>
</tr>
<tr>
<td>• diclofenac</td>
<td>Cattle and pigs</td>
<td>• 4.2.2002, 17.9.2003, 119 days, 471 days</td>
<td></td>
</tr>
<tr>
<td>• nafcillin (extension)</td>
<td>All ruminants</td>
<td>• 7.6.2002, 12.11.2003, 115 days, 390 days</td>
<td></td>
</tr>
<tr>
<td>• oxalic</td>
<td>Honey bees</td>
<td>• 11.9.2003, 10.12.2003, 90 days, 0</td>
<td>• 6.1.2004</td>
</tr>
<tr>
<td>• oxolinic acid (extension)</td>
<td>Cattle</td>
<td>• 11.12.2003, 10.12.2003, 90 days, 0</td>
<td>• 6.1.2004</td>
</tr>
</tbody>
</table>

1 Active time for the evaluation of the initial application and submission or responses to outstanding issues following the establishment of provisional MRLs and extension of the provisional MRLs.
## Annex 9
### COMP opinions in 2003 on designation of orphan medicinal products

#### Positive COMP designation opinions

<table>
<thead>
<tr>
<th>Product INN</th>
<th>Sponsor</th>
<th>Summary of Indication</th>
<th>EMEA/COMP</th>
<th>European Commission</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Alpha-1-acid glycoprotein</td>
<td>Bio Products Laboratory</td>
<td>Treatment of tricyclic anti-depressants poisoning</td>
<td>• 17.10.2002, 11.11.2002, 7.2.2003, 89 days</td>
<td>• 17.2.2003, 20.3.2003</td>
</tr>
<tr>
<td>Product INN</td>
<td>Sponsor</td>
<td>Summary of indication</td>
<td>EMEA/COMP</td>
<td>European Commission</td>
</tr>
<tr>
<td>------------</td>
<td>---------</td>
<td>-----------------------</td>
<td>-----------</td>
<td>---------------------</td>
</tr>
<tr>
<td>Product INN</td>
<td>Sponsor</td>
<td>Summary of indication</td>
<td>EMEA/COMP</td>
<td>European Commission</td>
</tr>
<tr>
<td>------------</td>
<td>---------</td>
<td>-----------------------</td>
<td>-----------</td>
<td>----------------------</td>
</tr>
<tr>
<td>• Recombinant dog gastric lipase (Merispase)</td>
<td>Meristem Therapeutics SA</td>
<td>• Treatment of cystic fibrosis • 6.3.2003 • 17.3.2003 • 13.6.2003 • 89 days</td>
<td>• Opinion received • 23.6.2003 • 9.7.2003</td>
<td></td>
</tr>
<tr>
<td>• hydroxyurea</td>
<td>OTL Pharma</td>
<td>• Treatment of sickle cell syndrome • 28.3.2003 • 2.5.2003 • 13.6.2003</td>
<td>• Start Date • 23.6.2003 • 9.7.2003</td>
<td></td>
</tr>
<tr>
<td>• Engineered protein inhibitor of human neutrophil elastase</td>
<td>Debioclinic SA</td>
<td>• Treatment of cystic fibrosis • 10.4.2003 • 2.5.2003 • 13.6.2003 • 43 days</td>
<td>• Opinion • 23.6.2003 • 9.7.2003</td>
<td></td>
</tr>
<tr>
<td>• adeno virus-Interferon gamma-coding DNA sequence</td>
<td>Transgene SA</td>
<td>• Treatment of Cutaneous T cell lymphoma • 25.2.2003 • 17.3.2003 • 13.6.2003 • 89 days</td>
<td>• Active Time • 23.6.2003 • 9.7.2003</td>
<td></td>
</tr>
<tr>
<td>• Herpes simplex virus lacking infected cell protein 34.5</td>
<td>Crusade Laboratories Ltd</td>
<td>• Treatment of glioma • 10.4.2003 • 2.5.2003 • 13.6.2003 • 43 days</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• prasterone (Fidelin)</td>
<td>Medicom Healthcare BV</td>
<td>• Treatment of adrenal insufficiency • 27.2.2003 • 17.3.2003 • 13.6.2003 • 89 days</td>
<td>• 23.6.2003 • 28.7.2003</td>
<td></td>
</tr>
<tr>
<td>• Antisense oligonucleotide (TATCCGGAGGGCTCG CCATGCTGCT) (NorVess)</td>
<td>Gene Signal SAS</td>
<td>• Treatment of neovascular glaucoma • 7.3.2003 • 2.5.2003 • 30.7.2003 • 90 days</td>
<td>• 7.8.2003 • 2.10.2003</td>
<td></td>
</tr>
<tr>
<td>• Alpha-1-acid glycoprotein</td>
<td>Bio Products Laboratory</td>
<td>• Treatment of cocaine poisoning • 13.5.2003 • 13.6.2003 • 30.7.2003 • 48 days</td>
<td>• 7.8.2003 • 2.10.2003</td>
<td></td>
</tr>
<tr>
<td>• 5,6,7,8-tetrahydrobiopterin</td>
<td>Prof Dr Adelbert A. Roscher</td>
<td>• Treatment of hyperphenylalaninemia • 27.5.2003 • 13.6.2003 • 30.7.2003 • 48 days</td>
<td>• 7.8.2003 • 2.10.2003</td>
<td></td>
</tr>
<tr>
<td>• Antisense oligonucleotide (TATCCGGAGGGCTCG CCATGCTGCT) (NorVess)</td>
<td>Gene Signal SAS</td>
<td>• Treatment of Retinopathy of Prematurity • 7.4.2003 • 2.5.2003 • 30.7.2003 • 90 days</td>
<td>• 7.8.2003 • 2.10.2003</td>
<td></td>
</tr>
<tr>
<td>• nolatrexed (Thymitaq)</td>
<td>SCIREX Ltd</td>
<td>• Treatment of hepatocellular carcinoma • 27.5.2003 • 13.6.2003 • 30.7.2003 • 48 days</td>
<td>• 11.8.2003 • 2.10.2003</td>
<td></td>
</tr>
<tr>
<td>• yttrium (90Y) antiferritin polyclonal antibodies (Ferritarg P)</td>
<td>Monoclonal Antibody Therapeutics</td>
<td>• Treatment of Hodgkin lymphoma • 10.4.2003 • 13.6.2003 • 30.7.2003 • 48 days</td>
<td>• 7.8.2003 • 2.10.2003</td>
<td></td>
</tr>
<tr>
<td>Product INN</td>
<td>Sponsor</td>
<td>Summary of indication</td>
<td>EMEA/COMP</td>
<td>European Commission</td>
</tr>
<tr>
<td>------------</td>
<td>---------</td>
<td>-----------------------</td>
<td>-----------</td>
<td>---------------------</td>
</tr>
<tr>
<td>• trabectedin (Yondelis)</td>
<td>Pharma Mar SA Sociedad Unipersonal</td>
<td>• Treatment of ovarian cancer</td>
<td>• Submission: 26.6.2003 • Start Date: 14.7.2003 • Opinion: 10.9.2003 • Active Time: 59 days</td>
<td>• Opinion received: 17.9.2003 • Date of decision: 17.10.2003</td>
</tr>
<tr>
<td>• eculizumab</td>
<td>QuadraMed</td>
<td>• Treatment of paroxysmal nocturnal haemoglobinemia</td>
<td>• Submission: 26.6.2003 • Start Date: 14.7.2003 • Opinion: 10.9.2003 • Active Time: 59 days</td>
<td>• Opinion received: 17.9.2003 • Date of decision: 17.10.2003</td>
</tr>
<tr>
<td>• H-tyrosine-glycine-phenylalanine-glycine-glycine-OH</td>
<td>Abiogen Pharma SpA</td>
<td>• Treatment of chronic idiopathic myelofibrosis</td>
<td>• Submission: 27.5.2003 • Start Date: 13.6.2003 • Opinion: 10.9.2003 • Active Time: 90 days</td>
<td>• Opinion received: 17.9.2003 • Date of decision: 20.10.2003</td>
</tr>
<tr>
<td>• Herpes simplex 1 virus-thymidine kinase and truncated low affinity nerve growth factor receptor transfected donor lymphocytes</td>
<td>MolMed SpA</td>
<td>• Adjunctive treatment in hematopoietic cell transplantation</td>
<td>• Submission: 25.6.2003 • Start Date: 14.7.2003 • Opinion: 10.9.2003 • Active Time: 59 days</td>
<td>• Opinion received: 17.9.2003 • Date of decision: 20.10.2003</td>
</tr>
<tr>
<td>• Human immunoglobulin</td>
<td>Orfagen</td>
<td>• Treatment of Dermatomyositis</td>
<td>• Submission: 25.6.2003 • Start Date: 14.7.2003 • Opinion: 10.9.2003 • Active Time: 59 days</td>
<td>• Opinion received: 17.9.2003 • Date of decision: 20.10.2003</td>
</tr>
<tr>
<td>• Human immunoglobulin</td>
<td>Orfagen</td>
<td>• Treatment of Polymyositis</td>
<td>• Submission: 25.6.2003 • Start Date: 14.7.2003 • Opinion: 10.9.2003 • Active Time: 59 days</td>
<td>• Opinion received: 17.9.2003 • Date of decision: 24.10.2003</td>
</tr>
<tr>
<td>• trientine dihydrochloride</td>
<td>Univar Ltd</td>
<td>• Treatment of Wilson’s disease</td>
<td>• Submission: 26.6.2003 • Start Date: 14.7.2003 • Opinion: 10.9.2003 • Active Time: 59 days</td>
<td>• Opinion received: 17.9.2003 • Date of decision: 24.10.2003</td>
</tr>
<tr>
<td>• gimatecan</td>
<td>Sigma Tau Industrie Farmaceutiche Riunite SpA</td>
<td>• Treatment of glioma</td>
<td>• Submission: 22.7.2003 • Start Date: 11.8.2003 • Opinion: 10.10.2003 • Active Time: 61 days</td>
<td>• Opinion received: 21.10.2003 • Date of decision: 1.12.2003</td>
</tr>
<tr>
<td>• Recombinant antibody derivative against human CD19 and CD3</td>
<td>Micromet AG</td>
<td>• Treatment of chronic lymphocytic leukemia</td>
<td>• Submission: 23.7.2003 • Start Date: 11.8.2003 • Opinion: 10.10.2003 • Active Time: 61 days</td>
<td>• Opinion received: 21.10.2003 • Date of decision: 1.12.2003</td>
</tr>
<tr>
<td>• vasoactive intestinal peptide</td>
<td>Mondobitech Laboratories Anstatt</td>
<td>• Treatment of Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension</td>
<td>• Submission: 27.3.2003 • Start Date: 14.7.2003 • Opinion: 10.10.2003 • Active Time: 89 days</td>
<td>• Opinion received: 24.11.2003 • Date of decision: 22.12.2003</td>
</tr>
<tr>
<td>• Recombinant antibody derivative against human CD19 and CD3</td>
<td>Micromet AG</td>
<td>• Treatment of Mantle cell lymphoma</td>
<td>• Submission: 23.7.2003 • Start Date: 11.8.2003 • Opinion: 10.10.2003 • Active Time: 61 days</td>
<td>• Opinion received: 21.10.2003 • Date of decision: 1.12.2003</td>
</tr>
<tr>
<td>• 5-methyl-pyridine-2-sulfonic acid</td>
<td>Axovan Europe Ltd</td>
<td>• Treatment of aneurysmal subarachnoid hemorrhage</td>
<td>• Submission: 25.7.2003 • Start Date: 11.8.2003 • Opinion: 6.11.2003 • Active Time: 88 days</td>
<td>• Opinion received: 17.11.2003 • Date of decision: 12.12.2003</td>
</tr>
<tr>
<td>Product INN</td>
<td>Sponsor</td>
<td>Summary of indication</td>
<td>EMEA/COMP</td>
<td>European Commission</td>
</tr>
<tr>
<td>---------------------------------------------------------------------------</td>
<td>----------------------------------------------</td>
<td>---------------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------</td>
<td>----------------------------------</td>
</tr>
<tr>
<td>• 3-(4’aminoisoindoline-1’-one)-1-piperidine-2,6-dione</td>
<td>Gregory Fryer Associates Ltd</td>
<td>• Treatment of multiple myeloma</td>
<td>• 20.8.2003 • 8.9.2003 • 6.11.2003 • 60 days</td>
<td>• 17.11.2003 • 12.12.2003</td>
</tr>
<tr>
<td>• 4,5-dihydro-2-(2,4-dihydroxyphenyl)-4-methylthiazole-4(S)-carboxylic acid</td>
<td>Genzyme Europe BV</td>
<td>• Treatment of chronic iron overload requiring iron requiring chelation therapy</td>
<td>• 21.8.2003 • 8.9.2003 • 6.11.2003 • 60 days</td>
<td>• 17.11.2003 • 12.12.2003</td>
</tr>
<tr>
<td>• Recombinant human factor XIII (composed of two A subunits)</td>
<td>Chiltern International Ltd</td>
<td>• Treatment of hereditary factor XIII deficiency</td>
<td>• 23.7.2003 • 8.9.2003 • 6.11.2003 • 60 days</td>
<td>• 17.11.2003 • 12.12.2003</td>
</tr>
<tr>
<td>• sildenafil citrate</td>
<td>Pfizer Ltd</td>
<td>• Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension</td>
<td>• 24.7.2003 • 11.8.2003 • 6.11.2003 • 89 days</td>
<td>• 17.11.2003 • 12.12.2003</td>
</tr>
<tr>
<td>• cilengitide</td>
<td>Merck KGaA</td>
<td>• Treatment of glioma</td>
<td>• 1.10.2003 • 17.10.2003 • 5.12.2003 • 50 days</td>
<td></td>
</tr>
<tr>
<td>• tacrolimus hydrate</td>
<td>Sucampo Pharma Ophthalmics Ltd</td>
<td>• Treatment of vernal keratoconjunctivitis</td>
<td>• 2.10.2003 • 17.10.2003 • 5.12.2003 • 50 days</td>
<td></td>
</tr>
<tr>
<td>• temocillin sodium</td>
<td>Bepharma NV</td>
<td>• Treatment of Burkholderia Cepacia lung infection in cystic fibrosis</td>
<td>• 21.5.2003 • 8.9.2003 • 5.12.2003 • 89 days</td>
<td></td>
</tr>
</tbody>
</table>

There were no negative opinions in 2003.
# Annex 10

## Guidelines and working documents in 2003

### CPMP Biotechnology Working Party

<table>
<thead>
<tr>
<th>Reference number</th>
<th>Document title</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPMP/BWP/2879/02</td>
<td>CPMP position statement on CJD and plasma-derived and urine-derived medicinal products</td>
<td>Adopted February 2003</td>
</tr>
<tr>
<td>CPMP/BWP/2289/02</td>
<td>CPMP points to consider on the development of live attenuated influenza vaccines</td>
<td>Adopted February 2003</td>
</tr>
<tr>
<td>EMEA/6011/03</td>
<td>Final EU recommendations for the influenza vaccine composition for the season 2003/2004</td>
<td>Adopted March 2003</td>
</tr>
<tr>
<td>CPMP/BWP/3068/03</td>
<td>Guidance on the description of composition of pegylated (conjugated) proteins in the SPC</td>
<td>Adopted July 2003</td>
</tr>
<tr>
<td>CPMP/BWP/1793/02</td>
<td>Note for guidance on the use of bovine serum in the manufacture of human biological medicinal products</td>
<td>Adopted July 2003</td>
</tr>
<tr>
<td>CPMP/BWP/3752/03</td>
<td>CPMP position statement on West Nile Virus and plasma-derived medicinal products</td>
<td>Adopted July 2003</td>
</tr>
<tr>
<td>EMEA/410/01 rev. 2</td>
<td>TSE revision of joint CPMP/CVMP note for guidance on minimizing the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products</td>
<td>Published in OJ C 24, 28.1.2004, p. 6</td>
</tr>
<tr>
<td>CPMP/BWP/5136/03</td>
<td>Discussion paper on the investigation of manufacturing processes for plasma-derived medicinal products with regard to vCJD risk</td>
<td>Adopted November 2003</td>
</tr>
<tr>
<td>CPMP/BWP/5092/03</td>
<td>CPMP biotechnology working party work programme for 2004-2005</td>
<td>Adopted December 2003</td>
</tr>
<tr>
<td>CPMP/BWP/1571/02</td>
<td>Position statement on the quality of water used in the production of vaccines for parenteral use</td>
<td>Adopted December 2003</td>
</tr>
<tr>
<td>CPMP/BWP/2758/02</td>
<td>Note for guidance on pharmaceutical aspects of the product information for human vaccines</td>
<td>Adopted December 2003</td>
</tr>
<tr>
<td>CPMP/BWP/3207/00 rev. 1</td>
<td>Guideline on comparability of medicinal products containing biotechnology-derived proteins as active substances: quality issues</td>
<td>Adopted December 2003</td>
</tr>
<tr>
<td>CPMP/BWP/3715/03</td>
<td>Procedural guidance on plasma master file (PMF) and vaccine antigen master file (VAMF)</td>
<td>Released for consultation October 2003</td>
</tr>
<tr>
<td>CPMP/BWP/3734/03</td>
<td>Note for guidance on scientific data requirements for a vaccine antigen master file (VAMF)</td>
<td>Released for consultation October 2003</td>
</tr>
<tr>
<td>CPMP/BWP/3794/03</td>
<td>Note for guidance on scientific data requirements for plasma master file (PMF)</td>
<td>Released for consultation October 2003</td>
</tr>
<tr>
<td>Reference number</td>
<td>Document title</td>
<td>Status</td>
</tr>
<tr>
<td>------------------</td>
<td>----------------</td>
<td>--------</td>
</tr>
<tr>
<td>CPMP/BWP/5180/03</td>
<td>Note for guidance on assessing the risk for virus transmission – new chapter 6 of the note for guidance on plasma-derived medicinal products (CPMP/BWP/269/95)</td>
<td>Released for consultation October 2003</td>
</tr>
<tr>
<td>CPMP/BPWG/BWP/561/03</td>
<td>Note for guidance on the warning on transmissible agents in summary of product characteristics (SPCs) and package leaflets for plasma-derived medicinal products</td>
<td>Released for consultation October 2003</td>
</tr>
</tbody>
</table>

**CPMP Ad Hoc Working Group on Blood Products**

<table>
<thead>
<tr>
<th>Reference number</th>
<th>Document title</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPMP/BPWG/BWP/561/03</td>
<td>Note for guidance on the warning on transmissible agents in summary of product characteristics (SPCs) and package leaflets for plasma-derived medicinal products</td>
<td>Adopted October 2003</td>
</tr>
<tr>
<td>CPMP/BPWG/1089/00</td>
<td>Note for guidance on the clinical investigation of plasma derived fibrin sealant products</td>
<td>Released for consultation March 2003</td>
</tr>
<tr>
<td>CPMP/BPWG/153/00</td>
<td>Core SPC for plasma derived fibrin sealant products</td>
<td>Released for consultation March 2003</td>
</tr>
<tr>
<td>CPMP/BPWG/3726/02</td>
<td>Core SPC for human Varicella immunoglobulin for intramuscular use</td>
<td>Released for consultation March 2003</td>
</tr>
<tr>
<td>CPMP/BPWG/3728/02</td>
<td>Core SPC for human rabies immunoglobulin for intramuscular use</td>
<td>Released for consultation March 2003</td>
</tr>
<tr>
<td>CPMP/BPWG/3730/02</td>
<td>Core SPC for human tetanus immunoglobulin for intramuscular use</td>
<td>Released for consultation March 2003</td>
</tr>
<tr>
<td>CPMP/BPWG/3732/02</td>
<td>Core SPC for human tick-borne encephalitis immunoglobulin for intramuscular use</td>
<td>Released for consultation March 2003</td>
</tr>
<tr>
<td>CPMP/BPWG/2048/01</td>
<td>Core SPC for human plasma coagulation factor VII products</td>
<td>Released for consultation March 2003</td>
</tr>
<tr>
<td>CPMP/BPWG/2231/99 rev. 1</td>
<td>Core SPC for human albumin</td>
<td>Released for consultation March 2003</td>
</tr>
<tr>
<td>CPMP/BPWG/278/02</td>
<td>Core SPC for human plasma derived von Willebrand factor</td>
<td>Released for consultation July 2003</td>
</tr>
<tr>
<td>CPMP/BPWG/220/02</td>
<td>Note for guidance on the clinical investigation of human plasma derived von Willebrand factor products</td>
<td>Released for consultation July 2003</td>
</tr>
<tr>
<td>Reference number</td>
<td>Document title</td>
<td>Status</td>
</tr>
<tr>
<td>------------------</td>
<td>----------------</td>
<td>--------</td>
</tr>
<tr>
<td>CPMP/BPWG/4027/02</td>
<td>Core SPC for human plasma derived hepatitis-B immunoglobulin for intravenous use</td>
<td>Released for consultation July 2003</td>
</tr>
<tr>
<td>CPMP/BPWG/4222/02</td>
<td>Core SPC for human plasma derived hepatitis-B immunoglobulin for intramuscular use</td>
<td>Released for consultation July 2003</td>
</tr>
<tr>
<td>CPMP/BPWG/3735/02</td>
<td>Core SPC for human plasma prothrombin complex concentrate</td>
<td>Released for consultation July 2003</td>
</tr>
</tbody>
</table>

**CPMP Ad Hoc Vaccine Expert Group**

<table>
<thead>
<tr>
<th>Reference number</th>
<th>Document title</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPMP/3390/02</td>
<td>Workplan for 2003-2004</td>
<td>Adopted January 2003</td>
</tr>
<tr>
<td>CPMP/VEG/4717/03</td>
<td>Note for guidance on dossier structure and content for pandemic influenza vaccine marketing authorisation application</td>
<td>Released for consultation November 2003</td>
</tr>
<tr>
<td>CPMP/VEG/4986/03</td>
<td>Guideline on submission of marketing authorisation applications for pandemic influenza vaccines through the centralised procedure</td>
<td>Released for consultation November 2003</td>
</tr>
</tbody>
</table>

**CPMP Efficacy Working Party**

<table>
<thead>
<tr>
<th>Reference number</th>
<th>Document title</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPMP/EWP/252/03</td>
<td>Concept paper on the development of a CPMP points to consider on clinical investigation of medicinal products in neuropathic pain management</td>
<td>Adopted February 2003</td>
</tr>
<tr>
<td>CPMP/EWP/49/01</td>
<td>Appendix to the note for guidance on the clinical investigation of medicinal products in the treatment of schizophrenia (CPMP/EWP/559/95) – methodology of clinical trials concerning the development of depot preparations of approved medicinal products in schizophrenia</td>
<td>Adopted February 2003</td>
</tr>
<tr>
<td>CPMP/EWP/633/02</td>
<td>Note for guidance on the clinical development of medicinal products for treatment of HIV infection</td>
<td>Adopted March 2003</td>
</tr>
<tr>
<td>CPMP/EWP/785/97</td>
<td>Points to consider on the evaluation of medicinal products for the treatment of irritable bowel syndrome</td>
<td>Adopted March 2003</td>
</tr>
<tr>
<td>Reference number</td>
<td>Document title</td>
<td>Status</td>
</tr>
<tr>
<td>-----------------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td>CPMP/EWP/2863/99</td>
<td>Points to consider on adjustment for baseline covariates</td>
<td>Adopted May 2003</td>
</tr>
<tr>
<td>CPMP/EWP/1343/01</td>
<td>Points to consider on the clinical evaluation of new agents for invasive fungal infections</td>
<td>Adopted May 2003</td>
</tr>
<tr>
<td>CPMP/EWP/967/01</td>
<td>Points to consider on the clinical development of fibrinolytic medicinal products in the treatment of patients with ST segment elevation acute myocardial infarction (STEMI)</td>
<td>Adopted June 2003</td>
</tr>
<tr>
<td>CPMP/EWP/205/95 rev. 2</td>
<td>Note for guidance on evaluation of anticancer medicinal products in man</td>
<td>Adopted July 2003</td>
</tr>
<tr>
<td>CPMP/EWP/569/02</td>
<td>Note for guidance on evaluation of anticancer medicinal products in man (CPMP/EWP/205/95 rev. 2) – addendum on paediatric oncology</td>
<td>Adopted July 2003</td>
</tr>
<tr>
<td>CPMP/EWP/3635/03</td>
<td>Concept paper on clinical investigation of medicinal products for the treatment of social anxiety disorder (social phobia)</td>
<td>Adopted September 2003</td>
</tr>
<tr>
<td>CPMP/EWP/4891/03</td>
<td>Concept paper on the development of a CPMP points to consider on clinical investigation of medicinal products for the treatment of Ankylosing Spondylitis</td>
<td>Adopted October 2003</td>
</tr>
<tr>
<td>CPMP/EWP/4713/03</td>
<td>Concept paper on the development of a CPMP points to consider on clinical investigation of medicinal products for the treatment of sepsis</td>
<td>Adopted November 2003</td>
</tr>
<tr>
<td>CPMP/EWP/556/95 rev. 1</td>
<td>Points to consider on clinical investigation of medicinal products other than NSAIDS for treatment of rheumatoid arthritis</td>
<td>Adopted December 2003</td>
</tr>
<tr>
<td>CPMP/EWP/788/01</td>
<td>Note for guidance on clinical investigation of medicinal products for the treatment of migraine</td>
<td>Adopted December 2003</td>
</tr>
<tr>
<td>CPMP/EWP/1875/03</td>
<td>Points to consider on the clinical requirements of modified release products released as a line extension of an existing marketing authorisation</td>
<td>Adopted December 2003</td>
</tr>
<tr>
<td>CPMP/EWP/225/02</td>
<td>Note for guidance on the evaluation of the pharmacokinetics of medicinal products in patients with impaired renal function</td>
<td>Released for consultation March 2003</td>
</tr>
<tr>
<td>CPMP/EWP/558/95 rev. 1</td>
<td>Note for guidance on evaluation of medicinal products indicated for treatment of bacterial infections</td>
<td>Released for consultation May 2003</td>
</tr>
<tr>
<td>CPMP/EWP/1875/03</td>
<td>Points to consider on the clinical requirements of modified release products released as a line extension of an existing marketing authorisation</td>
<td>Released for consultation June 2003</td>
</tr>
</tbody>
</table>
### CPMP Pharmacovigilance Working Party

<table>
<thead>
<tr>
<th>Reference number</th>
<th>Document title</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPMP/ICH/3945/03</td>
<td>ICH-E2D: Post-approval safety management: definitions and standards for expedited reporting and good case management practices</td>
<td>Adopted November 2003</td>
</tr>
<tr>
<td>CPMP/ICH/5716/03</td>
<td>ICH-E2E: Pharmacovigilance planning</td>
<td>Released for consultation November 2003</td>
</tr>
</tbody>
</table>
### CPMP Safety Working Party

<table>
<thead>
<tr>
<th>Reference number</th>
<th>Document title</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPMP/SWP/2599/02</td>
<td>Position paper on the non-clinical safety studies to support clinical trials with a single low dose of a compound</td>
<td>Adopted January 2003</td>
</tr>
<tr>
<td>CPMP/SWP/2965/03</td>
<td>Concept paper on the development of CPMP position paper on the contamination of control samples in toxicology studies</td>
<td>Adopted June 2003</td>
</tr>
<tr>
<td>CPMP/SWP/5958/03</td>
<td>Concept paper on the development of a CPMP. Note for guidance on the non-clinical investigation of the dependence potential of medicinal products</td>
<td>Adopted December 2003</td>
</tr>
<tr>
<td>CPMP/SWP/4447/00</td>
<td>Note for guidance on environmental risk assessment on medicinal products for human use</td>
<td>Released for consultation July 2003</td>
</tr>
</tbody>
</table>

### CPMP Herbal Medicinal Products Working Party

<table>
<thead>
<tr>
<th>Reference number</th>
<th>Document title</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>HMPWP/1416/02 rev. 1</td>
<td>Final proposal for a core-data* on <em>Urticae folium</em> (Nettle leaf)</td>
<td>Adopted July 2003</td>
</tr>
<tr>
<td>HMPWP/244/03</td>
<td>Final proposal for a core-data* on <em>Lini semen</em> (Linseed)</td>
<td>Adopted November 2003</td>
</tr>
<tr>
<td>HMPWP/1418/02</td>
<td>Final proposal for a core-data* on <em>Menthae piperitae folium</em> (Peppermint leaf)</td>
<td>Adopted November 2003</td>
</tr>
<tr>
<td>HMPWP/41/03</td>
<td>Final Position paper* on the use of herbal medicinal products containing asarone</td>
<td>Adopted November 2003</td>
</tr>
<tr>
<td>HMPWP/340/03</td>
<td>Final Position paper* on <em>Capsicum/capsaicin containing herbal medicinal products</em></td>
<td>Adopted November 2003</td>
</tr>
<tr>
<td>HMPWP/243/03</td>
<td>Proposal for a core-data* on <em>Primulae radix</em> (Primula root)</td>
<td>Released for consultation March 2003</td>
</tr>
<tr>
<td>HMPWP/341/03</td>
<td>Proposal for a core-data* on <em>Salicis cortex</em> (Willow bark)</td>
<td>Released for consultation July 2003</td>
</tr>
<tr>
<td>HMPWP/342/03</td>
<td>Proposal for a core-data* on <em>Urticae radix</em> (Nettle root)</td>
<td>Released for consultation July 2003</td>
</tr>
<tr>
<td>HMPWP/343/03</td>
<td>Proposal for a core-data* on <em>Thymi herba</em> (Thyme herb)</td>
<td>Released for consultation July 2003</td>
</tr>
<tr>
<td>HMPWP/337/03</td>
<td>Draft position paper* on the use of herbal medicinal products containing methyleugenol</td>
<td>Released for consultation July 2003</td>
</tr>
<tr>
<td>HMPWP/338/03</td>
<td>Draft position paper* on the use of herbal medicinal products containing estragole</td>
<td>Released for consultation July 2003</td>
</tr>
<tr>
<td>HMPWP/345/03</td>
<td>Draft position statement* on <em>Chamomilla containing herbal medicinal products</em></td>
<td>Released for consultation July 2003</td>
</tr>
<tr>
<td>HMPWP/344/03</td>
<td>Draft position paper* on the biopharmaceutical characterisation of herbal medicinal products</td>
<td>Released for consultation July 2003</td>
</tr>
</tbody>
</table>

* The views presented in this document are those of the HMPWP, which has been created as a forum for exchange of experience in the field of herbal medicinal products. This document is released for the purpose of transparency and has no legal force with respect to Directive 2001/83/EC.
### Ad-Hoc meeting on preclinical and clinical comparability of biotechnology medicinal products

<table>
<thead>
<tr>
<th>Reference number</th>
<th>Document title</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPMP/3097/02</td>
<td>Guideline on comparability of Medicinal Products containing Biotechnology derived Proteins as active substance: non-clinical and clinical issues</td>
<td>Adopted in December 2003</td>
</tr>
</tbody>
</table>

### ORGAM –Regulatory and Procedural guidelines

<table>
<thead>
<tr>
<th>Reference number</th>
<th>Document title</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>H/19984/03 rev. 1</td>
<td>Post-authorisation guidance document</td>
<td>Adopted in June 2003</td>
</tr>
</tbody>
</table>

### CVMP Efficacy Working Party

<table>
<thead>
<tr>
<th>Reference number</th>
<th>Document title</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>CVMP/625/03</td>
<td>Specific efficacy requirements for ectoparasiticides in cattle</td>
<td>Released for consultation July 2003</td>
</tr>
</tbody>
</table>

### CVMP Immunologicals Working Party

<table>
<thead>
<tr>
<th>Reference number</th>
<th>Document title</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>CVMP/205/03</td>
<td>CVMP advisory notice to veterinary surgeons regarding the development of fibrosarcomas at sites of injection of veterinary medicinal products in cats</td>
<td>Adopted March 2003</td>
</tr>
<tr>
<td>CVMP/042/97 rev. 1</td>
<td>Revised position paper on indications and specific claims for veterinary vaccines under the centralised procedure</td>
<td>Adopted June 2003</td>
</tr>
<tr>
<td>CVMP/550/02</td>
<td>Requirements for concurrent administration of immunological veterinary medicinal products</td>
<td>Adopted October 2003</td>
</tr>
<tr>
<td>CVMP/865/03</td>
<td>Position paper on the data requirements for removing the target animal batch safety test for immunological veterinary medicinal products in the EU</td>
<td>Released for consultation October 2003</td>
</tr>
</tbody>
</table>
### CVMP Pharmacovigilance Working Party (PhVWP-V)

<table>
<thead>
<tr>
<th>Reference number</th>
<th>Document title</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>CVMP/601/02</td>
<td>Points to consider regarding reporting of suspected serious adverse reaction to veterinary medicinal products: Common EU reporting form for marketing authorisation holders</td>
<td>Adopted February 2003</td>
</tr>
<tr>
<td>CVMP/065/03</td>
<td>Guideline on data elements for electronic submission of adverse reaction reports related to veterinary medicinal products</td>
<td>Adopted July 2003</td>
</tr>
<tr>
<td>CVMP/552/03</td>
<td>Causality assessment for adverse drug reaction to veterinary medicinal products</td>
<td>Released for consultation July 2003</td>
</tr>
<tr>
<td>CVMP/553/03</td>
<td>Points to consider list of species and breeds for electronic reporting of adverse reactions in veterinary pharmacovigilance</td>
<td>Released for consultation in July 2003</td>
</tr>
</tbody>
</table>

### CVMP General

<table>
<thead>
<tr>
<th>Reference number</th>
<th>Document title</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>CVMP/558/03</td>
<td>Future strategy on antimicrobial resistance</td>
<td>Adopted June 2003</td>
</tr>
</tbody>
</table>

### CVMP Safety Working Party

<table>
<thead>
<tr>
<th>Reference number</th>
<th>Document title</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>CVMP/457/03</td>
<td>Position paper regarding availability of veterinary medicinal products – extrapolation of MRLs</td>
<td>Adopted December 2003</td>
</tr>
<tr>
<td>CVMP/VICH/468/03</td>
<td>Repeat-dose (chronic) toxicity testing</td>
<td>Released for consultation May 2003</td>
</tr>
<tr>
<td>CVMP/VICH/467/03</td>
<td>General approach to establish a microbiological ADI</td>
<td>Released for consultation May 2003</td>
</tr>
<tr>
<td>CVMP/477/03</td>
<td>Position paper regarding availability of products for minor uses and minor species (MUMS)</td>
<td>Released for consultation June 2003</td>
</tr>
</tbody>
</table>

### CVMP Ad-hoc Group on Environmental Risk Assessment

<table>
<thead>
<tr>
<th>Reference number</th>
<th>Document title</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>CVMP/VICH/790/03</td>
<td>Environmental impact assessments (EIAs) for veterinary medicinal products (VMPs) phase II</td>
<td>Released for consultation October 2003</td>
</tr>
</tbody>
</table>
## Joint CPMP/CVMP Quality Working Party

<table>
<thead>
<tr>
<th>Reference number</th>
<th>Document title</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPMP/QWP/130/96</td>
<td>Note for guidance on the chemistry of new active substances</td>
<td>Adopted January 2003</td>
</tr>
<tr>
<td>CPMP/QWP/3309/01</td>
<td>Note for guidance on the use of near infrared spectroscopy by the pharmaceutical industry and the data requirements for new submissions and variations</td>
<td>Adopted February 2003</td>
</tr>
<tr>
<td>CVMP/961/01</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CPMP/ICH/2738/99</td>
<td>ICH Topic Q3B: Note for guidance on impurities in new drug products</td>
<td>Adopted February 2003</td>
</tr>
<tr>
<td>CPMP/ICH/420/02</td>
<td>ICH Topic Q1E: Note for guidance on evaluation of stability data</td>
<td>Adopted February 2003</td>
</tr>
<tr>
<td>CPMP/ICH/421/02</td>
<td>ICH Topic Q1F: Note for guidance on stability data package for registration in climatic zones III and IV</td>
<td>Adopted February 2003</td>
</tr>
<tr>
<td>CPMP/QWP/415/03</td>
<td>Concept Paper on the development of guidance on formulations of choice for paediatric population</td>
<td>Adopted February 2003</td>
</tr>
<tr>
<td>CPMP/QWP/609/96 rev. 1</td>
<td>Note for guidance on declaration of storage conditions for medicinal products particulars and active substances</td>
<td>Adopted April 2003</td>
</tr>
<tr>
<td>CPMP/QWP/450/03</td>
<td>Position paper on specifications for class 1 and class 2 residual solvents</td>
<td>Adopted April 2003</td>
</tr>
<tr>
<td>CVMP/422/99 rev. 2</td>
<td>Note for guidance on the declaration of storage conditions: a) in the product information of pharmaceutical veterinary medicinal products, and b) for active substances</td>
<td>Adopted July 2003</td>
</tr>
<tr>
<td>CVMP/680/02</td>
<td>Note for guidance on the quality of modified release dosage forms for veterinary use</td>
<td>Adopted July 2003</td>
</tr>
<tr>
<td>CPMP/QWP/4818/03</td>
<td>Concept paper on the development of note for guidance on stability of active substances and medicinal products manufactured in climatic zones III and IV and to be marketed in the EU</td>
<td>Adopted October 2003</td>
</tr>
<tr>
<td>CPMP/QWP/4812/03</td>
<td>Concept paper on the revision note for guidance on stability testing for variations</td>
<td>Adopted October 2003</td>
</tr>
</tbody>
</table>
Committee for Orphan Medicinal Products

Reference number  | Document title | Status                  
------------------|----------------|-------------------------
EMEA/4795/00 rev. 2 | General information for sponsors of orphan medicinal products | Adopted December 2003
## Annex 11
### Arbitration and Community referrals overview 2003


<table>
<thead>
<tr>
<th>Type of referral</th>
<th>Date of CPMP opinion</th>
<th>International non-proprietary name (INN)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Article 29</td>
<td>February 2003</td>
<td>clostridium botulinum type A neurotoxin</td>
</tr>
<tr>
<td></td>
<td>April 2003</td>
<td>isotretinoin</td>
</tr>
<tr>
<td></td>
<td>July 2003</td>
<td>fluconazole</td>
</tr>
<tr>
<td></td>
<td>Ongoing</td>
<td>amlodipine maleate</td>
</tr>
<tr>
<td>Article 7(5)</td>
<td>January 2003</td>
<td>salmeterol + fluticasone</td>
</tr>
<tr>
<td></td>
<td>March 2003</td>
<td>somatropin</td>
</tr>
<tr>
<td></td>
<td>May 2003</td>
<td>mononine</td>
</tr>
<tr>
<td></td>
<td>May 2003</td>
<td>factor VIII</td>
</tr>
<tr>
<td></td>
<td>July 2003</td>
<td>lisinopril</td>
</tr>
<tr>
<td></td>
<td>September 2003</td>
<td>desogestrel + ethinylestradiol</td>
</tr>
<tr>
<td></td>
<td>Ongoing</td>
<td>donepezil</td>
</tr>
<tr>
<td>Article 6(12) previously 7(5)</td>
<td>Ongoing</td>
<td>alendronate sodium</td>
</tr>
<tr>
<td>Article 30</td>
<td>March 2003</td>
<td>calcium folinate</td>
</tr>
<tr>
<td></td>
<td>April 2003</td>
<td>isotretinoin</td>
</tr>
<tr>
<td></td>
<td>June 2003</td>
<td>calcium carbonate</td>
</tr>
<tr>
<td></td>
<td>June 2003</td>
<td>calcium carbonate 500 + calciferol 10</td>
</tr>
<tr>
<td></td>
<td>June 2003</td>
<td>calcium carbonate 500 + calciferol 5</td>
</tr>
<tr>
<td></td>
<td>Ongoing</td>
<td>gemfibrozil</td>
</tr>
<tr>
<td></td>
<td>July 2003</td>
<td>perindopril</td>
</tr>
<tr>
<td></td>
<td>September 2003</td>
<td>lisinopril</td>
</tr>
<tr>
<td></td>
<td>November 2003</td>
<td>pravastatin</td>
</tr>
<tr>
<td></td>
<td>Ongoing</td>
<td>simvastatin</td>
</tr>
<tr>
<td>Article 31</td>
<td>September 2003</td>
<td>gatifloxacin</td>
</tr>
<tr>
<td></td>
<td>November 2003</td>
<td>celecoxib</td>
</tr>
<tr>
<td></td>
<td>November 2003</td>
<td>etoricoxib</td>
</tr>
<tr>
<td></td>
<td>November 2003</td>
<td>parecoxib</td>
</tr>
<tr>
<td></td>
<td>November 2003</td>
<td>rofecoxib</td>
</tr>
<tr>
<td></td>
<td>November 2003</td>
<td>valdecoxib</td>
</tr>
<tr>
<td></td>
<td>November 2003</td>
<td>loratadine</td>
</tr>
<tr>
<td></td>
<td>December 2003</td>
<td>nimesulide</td>
</tr>
<tr>
<td></td>
<td>Ongoing</td>
<td>paroxetine</td>
</tr>
</tbody>
</table>


<table>
<thead>
<tr>
<th>Type of referral</th>
<th>Date of CVMP opinion</th>
<th>International non-proprietary name (INN)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Article 34</td>
<td>Ongoing</td>
<td>Eprinex Pour-on (eprinomectin)</td>
</tr>
</tbody>
</table>
Annex 12

EMEA contact points

Pharmacovigilance and product defect reporting

The constant monitoring of the safety of medicines after authorisation (‘pharmacovigilance’) is an important part of the work of the national competent authorities and EMEA. The EMEA receives safety reports from within the EU and outside concerning centrally authorised medicinal products and coordinates action relating to the safety and quality of medicinal products.

For matters relating to pharmacovigilance for medicinal products for human use:

Panos TSINTIS
Direct telephone: (44-20) 75 23 71 08
E-mail: panos.tsintis@emea.eu.int

For matters relating to pharmacovigilance for medicinal products for veterinary use:

Barbara FREISCHEM
Direct telephone: (44-20) 74 18 85 81
E-mail: barbara.freischem@emea.eu.int

For product defect and other quality-related matters:

E-mail: qualitydefects@emea.eu.int
Fax: (44-20) 74 18 85 90
Out of hours telephone: (44-7880) 55 06 97

Certificates of a medicinal product

The EMEA issues certificates of a medicinal product in conformity with the arrangements laid down by the World Health Organisation. These certify the marketing authorisation and good manufacturing status of medicinal products in the EU and are intended for use in support of marketing authorisation applications in and export to non-EU countries.

For enquiries concerning certificates for centrally authorised medicines for human or veterinary use:

E-mail: certificate@emea.eu.int
Fax: (44-20) 74 18 85 95

Documentation services

A wide range of documents has now been published by the EMEA, including press releases, general information documents, annual reports and work programmes. These and other documents are available either on the Internet at http://www.emea.eu.int or by writing to:

EMEA Documentation service
European Agency for the Evaluation of Medicinal Products
7 Westferry Circus
Canary Wharf
UK – London E14 4HB

Further information (including general information packs) can be obtained from the above address or from:

E-mail: emearequests@emea.eu.int
Fax: (44-20) 74 18 86 70

Requests for general information packs should be sent to:

Amanda BOSWORTH
Direct telephone: (44-20) 74 18 84 08
E-mail: amanda.bosworth@emea.eu.int

European experts list

Approximately 3 000 are used by the EMEA in its scientific evaluation work. The list of these European experts is available for examination on request at the EMEA offices.

Requests should be sent in writing to the EMEA or to:

E-mail: europeanexperts@emea.eu.int

Integrated quality management

IQM adviser
Marijke KORTEWEG
Direct telephone: (44-20) 74 18 85 56
E-mail: iqmanagement@emea.eu.int

Press office

Press officer
Martin HARVEY ALLCHURCH
Direct telephone: (44-20) 74 18 84 27
E-mail: press@emea.eu.int